benefits ; cardiovascular system



EH


young woman ; family

HF
complications
cell ; Anand
doxorubicin
blood transfusions
FM

devices ; heart failure
dXA
Liver disease

HF ; pna

Renal artery stenosis

surgery ; heart transplant
hospital mortality
molecular mechanism
tertiary referral centre
EC
HF



mortality
breathing ; heart beat

DESIGN
heart failure ; Latin America


Heart

doctors
Nutrition ; heart failure
nordwest United States
Cross-sectional
unilateral
surgery
heart failure
INTERventions

Heart failure

clin
Sci
trans

CHF
autonomic balance
dynamique ; competitive
intermediate frailty
HFpEF


dodson

LV fibrosis ; ANS mice

Jehovahs Witness ; anemia
inpatient medical conditions
hospital ; heart failure
cardiac transplantation
CO
impact ; HF
cognitive function
Heart failure ; cognitive impairment ; mortality
HF ; HF
median follow-up
cardiology ; university hospital

Heart rate variability ; cardiac
Remote ischemic conditioning ; heart failure
air pollution ; heart failure

Sham-operated


policy


taxonomy
rates ; CHF
Heart failure ; uk

cardiovascular disease
HF ; MI

Heart failure ; disease
hemostasis

caspase ; heart
diuretic use ; heart failure
right heart failure ; pulmonary hypertension
Heart ; bisphosphonates

MR ; MS
hypertension
HF
Heart rate ; arterial pressure

Chronic HF
Cardiac amyloidosis
Robot-assisted training ; heart failure

Internal reliability ; cronbach
HFpEF
ejection fraction ; sex ; bNP
Pigs ; antiarrhythmic medication
beta blockade
CHF
surgical tactics ; circulatory arrest


systolic dysfunction
Literature

heart failure
implanted monitoring devices

patient safety ; conditions
HR ; afterload burden
strokes
Median age
RAS ; atherosclerosis
frailty in heart failure
microRNAs in heart failure ; disease management
cox regression
PSSS
management ; heart failure ; ejection fraction
Cardiology ; inhibition ; heart failure

vasopressin ; congestive heart failure
Mitral stenosis reversed ; medical treatment ; heart failure
heart failure hospitalization ; cardiovascular death
Trastuzumab-related cardiotoxicity ; breast cancer
implants ; heart failure ;HF
beneficial effect ; mortality
pde2 ; HF
Nights spent ; hospital
Heart failure ; public health
implante ; albumin
aortic pressure curve
physician continuity
Medication ; sST2
réseau meta-analysis
Cardiac
spironolactone ; systolic heart failure
eRK ; molecular scaffolds ; heart pathologie
fonctional MS ; degenerative MR
chronic heart failure ; bisoprolol
Heart failure ;HF ; mortality
cox proportional hazards
physician ; hospital ; physician specialty
Tolvaptan ; vasopressin ; receptor
Arrhythmia-related costs
metric choice ; readmission metrics
readmission metric

Median


black patients
ET ; CHF
reliability ; HF


propensity
hgb ; baseline HRQoL
ejection fraction
biomarkers ; chronic heart failure
HF ; cardiovascular hospitalization
cardiac ; inflammatory biomarkers
mortality
heart failure ; emergency department
Pharmacological treatment ; acute heart failure
heart failure
off-pump sternal sparing approach ; HeartMate II exchange
dialysis ; implantation
Coronary angiography
Hemodynamic ; failing Fontan
MS ; echocardiography


cox proportional hazard
Nordic walking
Psychometric testing ; Self-Care of Heart Failure Index
multiorgan failure ; sepsis
acute kidney injury
VO2max
cox proportional hazards models
Seattle Heart Failure Model
healthcare programmes
heart failure



abnormal cardiac


HR ; HF

drug ; Japan
biomarkers
mAIN oUTCOME MEasure ; tug
ESRD
Heart failure ; ventricular ejection fraction
mAIN oUTCOME
systolic HF
patient satisfaction
implantation
postsystolic
medication ; resting hemodynamics
pathophysiological origin
aac ; cardiac hypertrophy
AHA ; ESC
Physician ; heart failure
skeletal muscle abnormalities ; circulation
hospital ; heart failure
progressive disease ; hypertension ; kidney failure
chronic kidney disease ;CKd
gross income ; health per capita
hospital longitudinal change
HR ; sudden ; cardiac death
circulation
toxicity ; systemic blood pressure


therapy
enrollment
cPGs
MS

acute heart failure
patients ; heart failure
HF
end stage heart failure
HF
endothelial function ; flow-mediated dilatation
Race ; spironolactone ; heart failure
heart failure ; cardiac rehabilitation
Rhythm- ; rate-control
race ; exercise
anemia ; heart disease
physicians ; HF
Myocardial infarction ; Wistar rats
lVAD AI
AI
sinus rhythm ; AF
public reporting

services management ; telehealth ; medicare
filling pressures
ingenuity pathway
HF ; chromatin hyperacetylation
nursing
acute heart failure

ms
grLS ; CV ; AF
deficit index


mortality
hospitals
QRs

CHF ; unilateral renal DNx ; cardiac autonomic balance
Mitral regurgitation ; HF
renin-angiotensin-aldosterone system inhibitors ; heart failure
anaerobic threshold ; heart failure
MS
af ; echocardiographic examination
Nurses
économique savings ; coût
PVf ; PB ; amplitude

congenital heart lesions
MS ;HF ; surgical indication ; MS
ICU mortality
bioinformatic ; microarray ; heart failure
cardiovascular events
diuretic use ;HF
CAD ; cause ; systolic HF
inflammation ; metabolism ; heart disease
BB therapy
Heart block ; pulmonary artery snared ; BiVP

crte ; dialysis-dependent patients
beta-blockers
CHF
RM
HF
Cardiac function ; pressure-volume conductance catheter system
idiopathic dilated cardiomyopathy
unfolded protein ; cardiac sodium current ; systolic human heart failure
hypoalbuminemia
hypertensive LV dysfunction ; MR ; MS
cd HF
angiotensin receptor neprilysin inhibitor ; heart failure
Western blot ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
ischemic cardiomyopathy ; mortality
hff
implant ; ECCT
proteome ; HDL particles ; shotgun LC-MS ;MS
Frailty ; HF
Southeastern Minnesota residents ; HF
branch ; block electrical activation
hHF ; dp-4 inhibitors ; drugs
TAC ; pathways
Cardiac cachexia ;cc
signalling ; adaptive ; maladaptive cardiac remodelling
dialysis
neurological ; cardiovascular
coronary disease ; heart failure
ff ; FM ; body weight ; CC
multihospital study ; heart failure
Protective effects ; ed ; endothelial function
MS ; mva
social support ; barriers ; exercise
heart rate
cRF
Mediterranean ; DASh
rehospitalization
nitroxyl ; hno ; heart failure
Cardiac-resynchronization therapy ; heart failure
odds ; hospital clustering
change ; lVET ; follow-up
Blacks ; VO2
physician continuity ; urgent readmission ; discharge ; heart failure
hf ; HFpEF
hospital-to-Home ; hospital readmission reduction program ; congestive heart failure
risk ; hospitalization ; heart failure clinic
diabetes ; EO-cFUs
patient safety
transplants
Healthy ; aerobic exercise

trastuzumab-related CHF
hospitals
Peak VO2
pharmaceutically
FINDINGs
Coronary artery disease ;CAD ; systolic heart failure ;HF
hypoalbuminemia ; lVAD surgery
psoriasis ; atherosclerosis ; incident cardiovascular events ; Rotterdam
mortality ;HF hospital admissions ; transplant ; ventricular assist device
Heart failure ; rheumatoid arthritis ; tNF antagonist
holosystolic murmur ; heart sound
CV death ; non-fatal stroke ; heart failure
remodelling ;HF ; haemodynamic ; neuronal stressors
deficit ; biological phenotype ; mortality
ventricular function ; body composition ; heart failure
Fat ; cachexia ; right ventricle ; heart failure
atrial fibrillation ;AF ; heart failure
ECCT ; advanced heart failure therapy
heart transplantation ; left ventricular assist device
Exercise intolerance ; chronic heart failure
avd ; VVD ; co ; free wall RS
resistin ; heart failure
baseline ECGs ; electrocardiographers
ventricular assist device ; right ventricular support
ESRD ; outpatients ; HF
Wilcoxon
subclinical atherosclerosis
Renal artery stenosis ;RAS ; peripheral arterial disease
ECCT ; cardiac transplant recipients
eplerenone

transfusion
technique ; malfunctioning HeartMate ; lVADs
Heart failure ;HF ; cardiovascular hospitalization
VEGF inhibition ; b ; cardiac ; remodeling
β-blocker ;BB ; sST2
miRNAs ; cardiac
cPET guiding exercise rehabilitation ; CHF
heart failure ; ejection fraction
Patients ; heart failure
Pediatric heart failure ;HF
regulatory subunit ;RI ; HF
discharge ; medication
bromodomain proteins

heart failure
bt ; DT

hypotension
biomarkers ; HF
incident HF
ST2
économique
medications ; heart failure
mortality
coronary heart disease ; stroke ; heart failure
MLHF
septal defects
mortality ; iCD-HF
Unilateral renal denervation ; autonomic balance ; rabbits ; chronic heart failure

trastuzumab
hCT germline DNA
Heart failure disease management ; medical resource
Renal DNx ; circulating plasma NE ; CHF-INv rabbits
HF
blood work ; medication
NP assessment ; ED
Cardiac hypertrophy ; energy metabolism
implantation
HDL-bound malondialdehyde ; HDL-induced ; EC
renal dysfunction ; long-term survival ; transplant morbidity
CAD ; severe CAD
validity

survival ; hospital discharge
hospitals
anemia ; heart disease
Right atrial myxoma ; pulmonary embolism ; right heart failure
Nfat ; mir-25 ; transcription factor ; Hand2 in heart failure
resistin ; decline ; ejection fraction
Orthotopic heart transplantation ; oHT ; end-stage heart failure
Myxomas ; right atrium ; pulmonary arterial vasculature
change in readmissions ; heart failure
lVAS ; bridge to transplantation
Cardiac ; Mammalian enabled ;Mena ; heart failure ; mice
cPCs ; functional capacity ; VO2
dysfunction ; pump failure ; driveline injury
canine ; chronic heart failure ; tachycardia
Nicorandil ; doxorubicin
EH ; hpEF
eAST ; rhythm control therapy ; cardiovascular complications ; AF
radiological signs ;HF
diuretics ; congestive symptoms ; heart failure
fees
heart failure
Framingham Heart Study ; HF ; EF
HF
aCR ; CMS
caspase ; paced myocardium
Frailty ; risk ; heart failure ; aging ; body composition
hf ; saxagliptin ; sitagliptin
Heart t2 ; heart failure
ischemic ; inflammatory abdominal
ED ; intubations ; congestive heart failure
MedLine ; EMBAse ; cINAHL
aCP ; clinical practice guidelines
coronary artery disease ;CAD

responsiveness ; clinical change
ED visits ; CHF
QRs
Medicare ; post-acute care transfer policy
vegetables ; nuts ; whole grain intake

degs ; osprey ; réseaus

electronic databases ; World health Organization ; HF ; LA
deficit index
implantation ; cRT
benefit
iron
hospital discharge ; patients ; heart failure
LV filling pressure ; HF
Soluble ST2 ; ambulatory patients ; heart failure
implanting
Titin hypophosphorylation ; myocardial DD
ventricular contractile reserve ; pulmonary hypertension
bottleneck stent ; chronic myocardial ischemia ; heart failure ; pigs
QT intervals ; SD ; QT
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
benefit ; RAS- ; β-blocker uptitration ; HFpEF
injections
pump exchanges ; pump malfunctions ; pump thrombosis ; hemolysis
cardiac resynchronization ; dialysis-dependent patients ; heart failure
NOc ; admission
HRQoL ; hgb
inpatient records ; HF
skeletal muscle mass ; VO2
cardiac catheterization
psychosocial factors ; exercise ; heart failure ;HF
heart failure ; Canadian Cardiovascular Society guidelines
active treatment
aRIC HF
atrial fibrillation ; pacemaker
mortality ; iCD-HF
cardiovascular reason
AF-free probability ; catheter ablation ; sinus rhythm
body mass index ; cRF ; treadmill exercise testing
human myocardial tissue ; pKA subunits
paediatric cardiac transplants
ventricular-arterial coupling ; SV
diastolic failure ; cardiomyopathic restriction
autonomic nervous system activity ; QTV
pneumonia ; surgical conditions
mapping ; myocardial fibrosis


SD

ethics Rounds

biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
Heart Failure ; Pathophysiology ; Medical Treatment ; Nursing Management
anemia ; heart disease ; clinical practice guideline ; American College of Physicians
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
end-stage renal disease ; outpatients ; systolic heart failure
RVPO ; BiVP ; CO ; RS synchrony ; CS
renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
resistin ; acute anthracycline-induced cardiotoxicity
acute autonomic nervous system modulation ; QTV ; HF
Heart rate ; aortic blood flow ; doxorubicin
hospitalisations ; readmissions
Myocardial pde2 expression ; HF
BAT ; sympathetic outflow ; parasympathe
echocardiographic ; reverse remodeling ; cardiac resynchronization therapy
cardiovascular death ;HF ; btes
patients ; chronic heart failure ; lipoprotein functional properties
Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ;CHf
parasympathetic neurotransmission ; acetylcholinesterase inhibition
LVEF ; long-term mortality
Mediterranean ; DASh ; mortality ; women ; heart failure ; Womens Health Initiative
Jehovah's Witness ; sickle cell disease ; anemia
miRNAs ; heart failure
dobutamine ; furosemide ; oxygen flow
Health Buddy Program ; ED
ca2 ; currents ; rad ; congestive heart failure
cPCs ; diabetes
resistin ; anthracycline-treated breast cancer ; cardiotoxicity
pulmonary artery ; right pulmonary artery
mRI scanner ; heart failure

congestive heart failure ;CHf
muscle-wasting syndrome ; acquired heart failure
Frailty ; elderly
ed ; CHF ; intubation
bisoprolol ; mortality
Health Buddy Program ; content-driven telehealth system ; care management
Medicare fee-for-service beneficiaries
physician continuity ; conditions ; hospital discharge
patients ; heart failure
PSSS ; social support ; btes
cardiac stress ; β-AR drive
chromatin subproteome ; mouse heart
septal wall CS ; avd ; free wall CS ; VVD
LV ; echocardiography
implantation ; circulatory assist device
biventricular pacing ; left heart twist ; strain ; porcine model of right heart failure
etiologic causes ; RV failure ; left ventricular dysfunction
cPCs ; functional capacity ; heart failure ;HF
inhibition ; protein kinase ; soluble guanylate cyclase
circulating progenitor cells ; heart failure
Stress doppler echocardiography ; pulmonary hypertension
systolic ; diastolic mitral leaflet
morbidity ; mortality
ctnt ; NT-probNP ; HF
confidence intervals ;CIs
radiological signs
inhospital mortality ; bNP
Mortality ; aCS
ventricle ;RV ; cardiac function
coût ; patients ; heart failure ;HF
RV dysfunction ; weight loss ; fat ;lean body mass ratio
HR reduction ; beta blockers ; hFrEF
cardiopulmonary ; heart failure

i-mig myocardial washout
myocardial diastolic dysfunction ;DD
heart failure
baseline ST2
black race
Nursing-sensitive outcome change ; hospitalized older adults ; heart failure
therapeutic ; fluid overload
Human resistin ; chemotherapy-induced heart failure ; humanized male mice ; breast cancer
social support ; barriers
pressure ulcers ; surgical
HF ; valve plasty ; MS ; mva
p ; refractory ; end-stage congestive heart failure ;CHf
insurance status ; comorbidities
beta blockers ; heart failure
transcatheter
futility ; data ; safety
complication
chelation regimens ; heart iron
MT ; abdominal problems
Timed up ; Go test ; patients ; chronic organ failure
NYHA

mortality
ventricular ejection ; acute heart failure ; precapillary pulmonary hypertension
aortic valve insufficiency ; ventricular assist device implantation
ejection fraction ; cardiac resynchronization therapy ; mild heart failure
functional capacity ; mwt
hff ; dietary sodium restriction ; ventricular ; vascular stiffness
magnetically Levitéd left ventricular Assist System ; Treating Advanced HF
CHF atrial explants ; c-Kit ; implants
chronic heart failure ;CHf ; sympathetic tone ; autonomic imbalance
Heart failure ; mortality ; Western society ; cardiovascular diseases
extracorporeal membrane oxygenation ; bridge to recovery ; infarction-related refractory right heart failure
echocardiographic ; invasive hemodynamic
cardiac catheterization ; thrombotic obstruction ; right coronary artery
California office of Statewide Health Planning ; Development Patient Discharge Data
Fontan failure ; ventricular ; liver disease
hospitalized older adults ; HF
pacing-induced dilated cardiomyopathy
electromechanical delay ; dyssynchronous heart failure
trastuzumab ; cardiac

économique impact ; af ; heart failure ; Québec ; Canada
cardiac Mena deletion ; cardiac dysfunction ; hypertrophy
bundle-branch block ;LBBB ;LBBB
protein ; Western blot ; DNA fragmentation ; TUnel
Chinese herbal medicine ; dilated cardiomyopathy ; heart failure
implantable cardioverter-defibrillator deactivation
EH ; CH ; cardiac filling pressures
right atrium mass ; prolapse ; tricuspid valve ; stenotic physiology
NT-probNP
heart failure ; altered protein kinase
HF
temps-varying Seattle Heart Failure
dopamine ; nesiritide
chemical instability ; cogeneration ; nitrite
neurological ; cardiovascular
cox regression ; cardiovascular events ; psoriasis
cPG ; HF
HDL-induced ; production ; flow-mediated dilatation ; ET
aHF
systolic function
BETs ; mouse TAC model ; human HF
coût-effective ; participatory ; population-specific health interventions
cardiac nurses
consultations
transfusion ; mortality
Czech Republic
MADit-cRT ; device

UM/va/va-RT
risk ; heart failure
Western blots ; monoclonal antibodies ; Ser83 phosphorylation ; HF
ventricular assist device implantation
New York Heart Association ; quality-of-life
functional MS ; ring annuloplasty ; ischemic MR ; LV dilatation
Paco2 ; cerebral blood flow ; carotid bodies
vasopressin receptor antagonist ; tolvaptan ; Japanese heart failure
pathophysiology ; HF ; medical management
ED ; suburban hospitals ; New Jersey ; New York
psoriasis ; smoked ; diastolic blood pressure ; body mass index
Exercise intolerance ; heart failure
echocardiography ; implantation
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; pediatric heart failure
cox models ; ST2
TM interventions ; sts
HRQoL
NT-probNP ; circulation ; HF
energy metabolism ; heart failure ; hypertrophied heart
MS ; LV dilatation ; MS
PAD ; ankle-brachial index
HR reduction ; ivabradine ; TAC
mechanical cardiac support ; renal function
ECmo ; VAD ; ECmo+VAD
mortality ; morbidity ; cancers ; budget
anticoagulation ; therapy ; underlying heart disease
inotropic effect ; beta blockers
interleukin receptor family ; ST2 ; beta-blocker therapy ; chronic heart failure
implants ; heart failure
rhythm-control ; rate-control
hemoglobin
Functional MS
HF epidemiology ; health service provision ; HF ; LA
Heart failure ;HF ; debilitating chronic disease
heart failure ;HF
CF lVAD ; AI ; heart failure
anemia ; heart disease
ventricular dilatation
ventricular assist devices ; device therapies
implanted
renal dysfunction ; mechanical cardiac support
HF
computing readmissions ; hospital rankings ; pay-for-performance
cfa
PB ; HF ; pattern generator
Reasons

iCD

bNP ; NT-probNP ; biomarkers
Cardispiratory fitness ; body mass index ; heart failure mortality ; Cooper Center longitudinal Study
pro-adrenomedullin ;MR-proADm ; ff

Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
implantable cardiac defibrillator
ATP demand ; XO-mediated ROS ; mitochondrial respiration ; contractile
cardiovascular ; diabetes mellitus ; hypertension
systolic HF ; unclear etiology ; coronary angiography
atrial fibrillation ; congestive heart failure ; rhythm-control ; rate-control
ejection fraction ;EF ; infarct ; collateral growth ; myocardial perfusion
Circulating ; N-terminal pro-B-type natriuretic peptides ; plasma ; heart failure
heart failure ;HF ; left ventricular ejection fraction ;HFpEF
implantation ; long-term ventricular assist device
HF ; cardiac murmurs ; blood pressure ; hg
adenylyl cyclase ; g-protein coupling
HF ; spontaneous VT ; beat-to-beat QT
biventricular dysfunction ; HeartMate II
TUg test ; patients ; advanced COPd ; CHF ; cRF
passages ; pressure-overload-induced heart failure
social mandate
hemodynamically unstable ; cPR
isoproterenol ; cXL-1020 ; myocytes ; hearts
cardiac angiogenesis ; in vivo coronary perfusion ; cardiac fibrosis
implantation ; heart failure ; ventricular tachycardia
Pyridostigmine ; myocyte diameter ; collagen density ; ventricle
Exercise intolerance ; hff ;qol
energy substrate metabolism
structure ; SCHFI
CAD
diabetes mellitus ; cardiovascular disease
CVd ; psoriasis
haemodynamic ; pulmonary
prediction rule
Rotterdam ; psoriasis ; cardiovascular outcomes
HR ; tNF antagonists ; nbDMARD
aCS ; MT ; VAD
hospital ; cardiac specialty hospital ; rural South dakota
structure ; medical records
ECmo ; egFR ; egFR
trastuzumab-related CHF
acute HF
biomarker-guided clinical
hospitals
long-term survival
sudden cardiac death
HF-related cachexia ; RV ; body composition
hospital mortality
hospital ; rehospitalization
cognitive impairment ; mortality
sonographic ; histological ; functional abnormalities
natriuretic peptide ; biomarkers
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
Spironolactone ; hyperkalemia ; acute kidney injury
bNP ;PAD ; bNP ; HF
sympathetic ; parasympathetic activity ; HF
EH ; systolic blood pressure ; renal impairment ; hypertension
race ; HF
mouse HF ; transition ; compensated LV hypertrophy ; HF ; hHD
ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
heart transplantations ;LV assist device implantations ; heart failure
chronic myocardial ischemia ; heart failure
HFpEF
mechanical cardiac support ; renal function ; end-stage heart failure
surgical revascularization
hgb ; kccq
Morpholino-based knockdown ; nucleolin ; protein expression
clinical prediction rule ; CAD ; cause of systolic HF
pump-exchange technique ; redo sternotomy ; cardiopulmonary bypass
MS ; HF ; functional MS
parasympathetic function ; HF evolution
HF ; HF ; ms ; mva
jugular venous pressure ; peripheral oedema
Heart failure ;HF
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
Fontan circulation ; sVR index ; cardiac index
lVAD ; biventricular support
mineralocorticoid receptor antagonists
hereditary ; congenital abnormalities ; heart
Fontan circulation ; skeletal muscle mass ; metabolic abnormalities
HeartMate II lVAD

health insurance ; health system data ; ues ; Food and Drug Administration ; Mini-Sentinel program
NT-probNP ; ED ; acute heart failure
blacks ; hypertension ; diabetes ; ischemic etiology ; socioeconomic status ; whites
albumin ; lVAD
réseau ; Cytoscape ; functional enrichment
cardiovascular conditions ;HF
patient safety
HF-induced remodeling ; EMd prolongation
right heart circulation ; right heart failure
Raf-MEK1/2-ERk1/2 signalling ; remodelling
MI ; late-onset ; MI ; HF
Bisphosphonate ; heart failure
coût ; survival
sustainability ; commissioning ; hospital-based programmes
maladaptive molecular
Xanthine oxidase inhibition ; ventricular systolic ; diastolic ; cardiac
heart failure ; preserved ejection fraction ; clinical doppler echocardiography
heart failure ;HF ; Heart Failure Adherence ; retention Trial ;HARt
HF ; ejection fraction ;HFpEF ; hypertension
NYha functional class ; quality-of-life score
Myocardial infarction ; left anterior descending coronary artery occlusion
HFpEF ; breathlessness ; fatigue
immunodetection ; NT-probNP ; antibodies
Nordic walking ; cardiac rehabilitation ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
β-Blockade ; cardiac angiogenesis ; heart failure ; VEGF signaling pathway
myocardial ischemic events ; cardiac resynchronization therapy
aortic valve surgery ; new-onset ; lVAD AI
unloading ; heart ; HR reduction ; systolic heart failure
spironolactone ; systolic heart failure
Heart failure ; medicine ; atheromatous coronary disease
Heart failure ;HF ; Latin America ;LA ; health service planning ; HF
medicare fee-for-service beneficiaries ; skilled nursing facilities
HF ; crte ;hazard ratio
palliative
HFpEF
oxidative stress ; GTPase Rac1 activity ; hearts ; ANS mice
circulating mediator of insulin resistance ; human monocytes ; inflammatory stimuli
cardiovascular death ; urgent cardiac transplant
medications ; heart failure ; NCDR PINNACLE
beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure

transformed
Intravenous iron ; heart failure ; iron deficiency
heart failure ; Emergency Department ;ED ; ED
conditions ; maladaptive remodelling ; heart failure
degs ; non-ischemic ; ischemic heart failure
psoriasis ; systemic/UV
RV dysfunction ; weight loss ; abnormal body composition ; HF


diastolic dysfunction ; hFPEF
adrenergic receptor blockade ; heart failure ;HF
ventricle overload ; stroke volume ; ventricular ejection time ; lVET
NT-probNP ; HF patient plasma ; immunoprecipitation
Chromatin-associated proteins ; chromatin structure ; DNA
PD ; therapy ; HF
pulmonary hypertension ;PH ; heart failure
robot-assisted gait therapy ; Lokomat® system in heart failure
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
ET ; HDL function ; ET ; CHF-NYha-IIIb ; HDL
Cardiac failure ; diabetes ; diabetes ; heart failure
implantation ; hemodynamic status
lVET ; ICU
congestive heart failure
aim ; implantable cardioverter-defibrillator deactivation
mitochondrial structure
heart failure ; ejection fraction
gut ; inflammation ; heart failure
pPR ; aCR ; CMS
LCx ; LAD ; two-vessel disease model
CHF ; emergency department ;ED ; intubated
CHF ; therapeutic interruption ; activated neurohormonal systems
zf1 rats ; heart failure ; preserved ejection fraction
physician follow-up ; discharge ; death ; readmission ; heart failure
heart magnetic resonance imaging ; chelation choices ; heart disease ; thalassaemia
arterial tonometry ; lVET ; precapillary PH ; heart failure
Cross-talk ; heart ; adipose tissue ; cachectic heart failure
mutant mice ; Hand2 ; heart muscle cells ; pathological hypertrophy
transoesophageal echocardiography
heart rate ; renal function ; spironolactone
dialysis ; echocardiographic
microRNAs ;miRNAs ; heart failure
PARADIGm-HF ; paradigm shift ; chronic heart failure ; Chronic heart failure ; cardiology
consenting ambulatory HF ; left ventricular ejection fraction
New Zealand White rabbits ; renal DNx ; pacing-induced CHF
QT variability ; qTV ; repolarization lability ; QTV ; risk predictor ; sudden cardiac death
Beta-blocker
mRI ; tidal respiration ; myocardial t1 ; swine ; heart failure
cardiovascular disease
technologies
psoriasis ; cardiovascular disease ;CVd
Hospital Compare ; AMI mortality rates

proteins
Rhythm control therapy
e-septal

cardiac dysfunction ; subcellular alterations ; metoprolol ; heart failure ; myocardial infarction
LV diastolic dysfunction ; filling pressures ; doppler echocardiography
Cardiac magnetic resonance ; heart failure ; ejection fraction
Myocardial collagen ; collagen ; titin isoforms ; phosphorylation
RAS-blocker uptitration ; hFrEF ; HFpEF
Hemoglobin ; health status ; patients ; chronic heart failure ; HF-ACtion
Systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
Plasma ; HF
pde2-overexpressing cardiomyocytes ; norepinephrine-induced hypertrophic
heart failure ; CLCNKA sNP
GDMT ; GDMT ; BAT
hz
transduction ; signalling proteins
alendronate ; risk ; heart failure
cardiovascular disease ; dRS
index admission

beta-blocker therapy
heart failure ; bisphosphonates
frailty ; risk ; heart failure ;HF
miRNAs ; cardiac remodeling ; heart failure
HF
diastolic dysfunction ; cause mortality
AlphaLISa ; immunoassays ; NT-probNP
Fontan ;SAF
c-statistics ; biological phenotype
sinus rhythm ; antiplatelet agents ; anticoagulants
implantable cardioverter-defibrillator deactivation
heart failure ; left ventricular ;LV ; ejection fraction
cardiotoxicity ; doxorubicin ; anti-neoplastic agent
aCS ; oHT ; transplant ; MT ; VAD
natriuretic peptides
RAS- ; β-blocker
β-Blocker-induced enhancement ; cardiac angiogenesis ; therapy ; cardiac function
HF ; rheumatoid arthritis ;RA
Bax ; bcl-2 proteins ; dogs
PRInciPAL FINDINGs ; hospital rates ; HF ; CMS ; conditions
regulation of feeding ; anti-inflammatory effects ; CHF
lifesaving drugs ;HF ; ejection fraction ;HFrEF
hyperkalemia ; kidney injury ; spironolactone
Renal denervation ;DNx ; CHF
MT ; VAD ; aCS
refractory congestive heart failure ; peritoneal dialysis
Mammalian enabled ;Mena ; cytoskeletal actin dynamics ; heart failure ;HF
heart failure ; left atrial pressure
Heart failure ; preserved ejection fraction ; hff ; cardiovascular reserve
LV diastolic dysfunction ; hff
physician follow-up ; physician continuity ; heart failure
ambulatory iCD patients ; predictor ; mortality
ARNI inhibitors ;angiotensin-receptor neprilysin inhibitors
Gastrointestinal bleeding ; ventricular assist devices
nicorandil ; cytotoxic effect ; doxorubicin ; Ehrlich carcinoma
Myxomas ; cardiac benign tumors ; left atrium
fes ; preserved ejection fraction ;HFpEF
bNP ; NT-probNP ; coronary artery disease ;CAD

NT-probNP
ECCT
aerobic capacity ; left-hand grip strength ; body weight ; waist circumference
Process redesign
Myocardial loss ; iRS1 ; iRS2 ; heart failure ; maPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
Functional mitral stenosis ;MS ; ring annuloplasty ; ischemic mitral regurgitation ;MR
ICU admission ; precapillary PH ; heart failure
heart failure-related hospitalization ; ventricular ejection fraction
Heart failure ; preserved ejection fraction ;HFpEF ; cardiovascular morbidity
tissue doppler imaging ; left ventricular filling pressure ; systolic heart failure
lean ZSF1 group ; hypertensive ; obese ZSF1 ; diabetic
heart failure ; preserved ejection fraction ; hff
Kansas City Cardiomyopathy ; heart failure ; ejection fraction
myocardial pde2 ; intracellular antiadrenergic therapeutic strategy ; HF
benefits ; spironolactone
HF
IE ; heart failure ;HF ; cRT-d
pharmacologic treatment ; clinical trials
Mechanical dyssynchrony ; QRS complex ; cRT
coronary occlusion ; collateral growth
carotid intima-media ; psoriasis
transfusions ; heart disease
VO2 ;joint effect
PVf ; PB cycle ; BP
chronic heart failure ; Hungary
RV dysfunction ; cardiac cachexia
Remote monitoring ;RM ; heart failure
eCG ; cRT
sST2 ; b ; cardiovascular event
breast cancer patients ; trastuzumb-related CHF
HF remodeling ; EMd ; dyssynchronous failing heart
acute heart failure ; aHF ; heart failure ;HF
angiogenesis ; post-myocardial infarction heart ; heart failure
aldosterone antagonist ; heart failure
surgery ; HF ; hypertension ; vasodilators ; diuretics
Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
HR reduction ; beta-blocker therapy
pde2 ; failing hearts ; β-AR
psoriasis ; atherosclerosis ; cardiovascular events
anemic ; iron-deficient adult patients ; heart disease
heart failure ; hospitalisation
egFR ; diuretics ; hypertension ; ESRD
trastuzumab ; CHF ; nontrastuzumab
e-cFUs ; mortality
point-of-care systems ;NP ; ED ; community outpatients ; acute heart failure
heart failure ; ejection fraction ; myocardial infarction
lVAS
black race ; HF hospitalization ; cardiovascular mortality
cardiac disease ; heart failure
hff
physician adherence ; HF cPGs
HF ; HF ; HF mortality
HDL function ; CHF ; ET ; HDL-mediated vascular effects
coronary artery disease ; systolic heart failure
Shunt implants ; transseptal catheterisation ; transoesophageal echocardiographic guidance
arterial compliance ;TAC ; end-systolic elastance ; ees
biventricular support ; HeartMate ; lVAD ; CentriMag RVAD
Renal dysfunction ; long-term mortality ; myocardial infarction ; coronary artery bypass grafting ;CABG
cardiovascular ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; HFpEF
isoprenaline infusion ; SDQT ; hNorm ; HF
Renal dysfunction ; cardiovascular events ; caBG
Pyridostigmine ; vascular endothelial growth factor ; ventricle ; myocardial angiogenesis
egFR ; VAD ; ECmo+VAD group ; ECmo
CHF ; international Classification of Diseases
RV dysfunction ; body mass index ; fat mass index ; cachexia
baseline cRF ; HF mortality ; HF
Robot-assisted gait therapy ; Lokomat® System ; heart failure
cardiac growth ; plasticity ; disease recapitulates ; chromatin remodeling
idiopathic dilated cardiomyopathy
dopamine ; nesiritide
MEDline ; EMBAse ; cochrane databases ; clinical trial registries
Clinician
HF
Ea ; TAC ; HR ; ees ; ivabradine-
Care management coupled ; content-driven telehealth technology ; health outcomes ; high-cost Medicare beneficiaries
ERC ; pure epicatechin
biomedical reasons
myocardium ; pka subunits ; downstream signaling
therapy ; atrial fibrillation ; carvedilol ; metoprolol
implantable cardioverter-defibrillator
functional MS ; valve plasty ; degenerative MR ; LV
HeartMate II insertion ; biventricular support ; implantation
management ; end stage heart failure Heart failure ; public health ; europe ; nord America
st-segment-elevation MIs ; Killip class
heart failure ; mechanical support devices ; Cardiology-cardiovascular Surgery Consensus ; Heart failure ; progressive disease
elastic N2Bus segment ; PEvk segment
Self-Care of Heart Failure Index ;SCHFI ; psychometric profile
proteomics ; chromatin-associated proteins ; detergent
HeartMate ; left ventricular assist system ; lVAS ; patients ; advanced heart failure
Nicorandil ameliorates mitochondrial dysfunction ; doxorubicin-induced heart failure ; rats ; cardioprotection
pharmacologic management ; acute HF ; chronic HF
arterial elastance ; pulsatile afterload ; heart ; pressure
cXL-1020 converts ; hno ; inactive ; cXL-1051
tNF antagonists ; HF hospital admissions ; nbDMARDs ; RA
ejection fraction
grs ; h ; CV

risk-adjusted mortality
nurses
physician adherence ; class I recommendations
HF ; PAf biosynthetic enzymes ; lyso-paf-AT
myocardial infarction ;MI ; heart failure ;HF
cardiac magnetic resonance imaging ; mapping ; invasive hemodynamic assessments
Heart rate reduction ; exercise ; heart failure ; ejection fraction ; beta-blocker hypo-response
RAS ; hypertension ; nephropathy
brain natriuretic peptide ; bNP ; creatinine ; natremia
mADIt-crte ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
NT-probNP ; MR-proanp ; MR-proadm
isoelectric focusing ; RIα ; ser77 ; ser83 ; phosphorylation sites
SDQT ; SD ; RR ;SDRR ; QTV ; heart rate variability
aUCs ; eseptal ; eemean ;septal ; QRs width
Logistic regression models
IVc occlusion ; CO correlated ; twist ; apical rotation ; RS ; RS synchrony ; CS
hospital stay ; congestive heart failure
diuretics ; modulate HF-related morbidity
hospital ; patients ; heart failure
devices ; gastrointestinal bleeding
cardiac events
egFR ; VAD group ; ECmo+VAD group ; renal function
sST2/low-dose BB ; sST2/high-dose BB
CHF visit ; ED visits ; CHF patients intubated
Physician volume ; mortality ; HF ; noncardiologist physicians
zebrafish ; nucleolin ; genomic reprogramming events
LV ejection fraction ; PCWP
HF complicating AMI ; mortality
emergency department ; acute heart failure clinical trials
cardiopulmonary exercise ; muscular strength ; peak quadriceps force
public health ; air pollution ; urban ; industrial areas ; cardiovascular health
eCG ; ion channelopathies ; cardiomyopathy
idiopathic dilated cardiomyopathy ; tuscany
HF ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
Morbidity ; mortality ;HFpEF ; HF ; EF
HF ;heart failure ; t2d ; diabetes ; Skm ;skeletal muscle
heart failure ;HF ; inpatient ; outpatient models
molecular biomarkers ; pathophysiology ; chronic HF
carvedilol ; metoprolol ; heart failure ; devices
Erythropoiesis-stimulating agents ; anemia ; heart disease
intravenous iron ; heart failure
mitral valve plasty ; degenerative mitral regurgitation
in-trial resource utilization ; coût ; Québec Health Insurance Board ; disease-specific costs ; Ontario Case Costing Initiative
BET bromodomain-containing protein ;BRd4) ; cardiac tissues
RAS ; neprilysin inhibition ; chronic heart failure ; systolic dysfunction

end-stage heart failure ; pediatric mechanical cardiac support
économique models ; lVAD
echocardiographic score ; cRT
ejection fraction
AF ablation
If-channel inhibition ; hemodynamic status ; heart failure ; preserved ejection fraction
tidal respiration ; gadolinium-chelate contrast agent
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
Medicare inpatient ; HF admissions ; acute care hospitals ; United States
catheter ablation ; atrial fibrillation ; heart failure ; preserved ejection fraction
dopamine ; nesiritide ; acute heart failure ; renal dysfunction ; ROse acute heart failure
DAPc ;dystrophin-associated protein complex ; sarcomeric microstructure
mouse HF ; hh ; salt loading ; uninephrectomy ; ANG II infusion
Benefits ; HF ; ejection fraction ; pEF ; uptitration
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; rat metabolic risk
echocardiographic predictors ; response ; cardiac resynchronization therapy ; cRT
baseline serum creatinine ; serum potassium
chromatin subproteomes ; heart failure ; chromatin structure
Hum- retn mice ; cardiac mRNA ; inflammatory ; cell adhesion ; Retn ; mice
anemia ; chronic heart failure ;HF
University of Connecticut Heart Failure Center ; cardiologist ; heart failure nurse practitioner
NT-probNP ; antibodies ; nonglycosylated
RV failure ; intrinsic left ventricular dysfunction
PD ; diuretic response ; edema ; functional class
Chronic heart failure ; transforming growth factor beta-dependent yield ; functional decline ; atrial explant-derived c-Kit
HFpEF ; kccq
HeartMate II lVAD ; temporary CentriMag RVAD
implantation ; heart failure
h ; MI ; preserved ; reduced ejection fraction ;EF
Mortality ; inpatient admissions ; hospital days ; emergency department ;ED
nbDMARD ; tNF antagonist
trastuzumab ; cardiotoxicity ; congestive heart failure ;CHf
pyridostigmine administration ; methylatropine ; propranolol ; cardiac sympathovagal balance
uPR ; protein kinase ; ER kinase ;perk ; calreticulin ; CHOp ; HF
myosin binding protein-C phosphorylation ; Ser23/24 troponin I phosphorylation ; HF
echocardiographic ; N-terminal pro-brain natriuretic peptide ; inflammatory markers
Phosphodiesterase-2 ; failing hearts ; blunts beta-adrenergic responses ; cardiomyocytes
carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype
hFrEF ; exercise performance ; resting HR ; beta-blocker therapy
PAf ; metabolic enzymes ; heart failure
XO inhibition ; cardiomyocyte bioenergetics ; LV ; chronic aCF ; rat
randomised-controlled trials ;rcs
cox hazard models ; temps ; ESRD ; death ; ESRD ; death ; ESRD
renal dysfunction ; stroke ; myocardial infarction ; heart failure ; CABG
heart failure ;HF ; cardiopulmonary exercise ; anaerobic threshold
Patients ; heart failure ; heart failure nurses ; cardiology services
hf ; pyridostigmine ; stroke ; ejection fraction ; cardiac output ; contractility ; left ventricle
recreational athletes ; sudden cardiac deaths ; atherosclerotic CAD
rheumatic ; MS
Womens Health Initiative ; HF
CHF ; infarcted animals ; left ventricle end-diastolic pressure ; hg
RV ; pathophysiologic mechanisms ; RV dysfunction
dialysis-dependent patients ; HF ; implantation
Peak oxygen ; oxygen pulse
économique climate ; NHs ; behavioural-change ; chronic disease
hCT CHF ; hCT ; City of Hope

pigs ; inferior vena cava ;IVc ; CO
doxorubicin ; ip ; serum resistin ; Hum-retn mice
costs ; high-volume physicians ; hospital
nutritional abnormalities ; CHF
deactivation
aldosterone receptor antagonists ; morbidity ; mortality ; systolic heart failure
sCN5a transcript ; uPR ; downregulation ; cardiac genes ; HF
eAST ; rhythm control therapy ; AF ; cardiovascular complications ; AF
albumin ; inflammation ; hepatic function ; implantation
Right ventricular ;RV ; insertion ; left ventricular assist device ; lVAD
tAPse ; PASp ; tAPse
cox proportional hazards models ; health behaviors ; health status
lipolysis ; energy expenditure ; natriuretic peptides ;NPs ; CC
CV deaths ; non-fatal stroke ; heart failure
hearts ; Mena ; cardiac injury ; Mena ; HF pathophysiology
biomarkers ; molecular dysfunction
ST2 ; risk ; c statistic ; discrimination
grs ; index beat ; CV ; cox proportional hazards
non-ischemic ; ischemic heart failure ; biomarkers ; heart failure
VAD ; ECmo+VAD group ; ECmo group
air pollution ; cardiovascular health ; acute myocardial infarction
kccq ; Kaplan-Meier curves ; death
RAS ; doppler ultrasonography ; computed tomographic angiography ; magnetic resonance angiography
Testosterone therapy ; exercise rehabilitation ; patients ; chronic heart failure ; testosterone
renal underperfusion ; renin- angiotensin-aldosterone
AMI ; heart failure ; kidney infection ; UTI
proteomics ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
IC ; multicenter Automatic Defibrillator implantation ; Trial-Cardiac resynchronization Therapy
Olmsted County ; Minnesota ; MI ; HF
Health Buddy Program ; chronic obstructive pulmonary disease ; mortality ; congestive heart failure
HF
odds ratio ;hazard ratio ; death ; HF ;AMI
neurohumoral blockers ; HF ; co-morbidity burden
ventricular ejection fraction ; long-term mortality ; heart failure ; Heart Failure Survey ; ISrael
vascular endothelial growth factor ;VEGF ; transition ; compensatory hypertrophy ; cardiac failure
sensitivity ; CAD ; severe CAD
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD
apoptosis ; heart failure

diuretic efficacy ; neurohormonal activation ; fluid
uPR ; na+ channel mRNA splice ; cardiac ; na+ current ; hz
LVEF ; LVEF
lVAD ; transplantation eligibility status
BETs ; transcriptional pause release ; re-activation transcription ; pathological stress
eCG ; atherosclerotic CAD ; sudden cardiac death
HF ; index AMI ; hazard ratio ; mortality
cRT-d ; IE ; defibrillator-only therapy
HR dynamics ; temps-domain ; HR variability ; risk stratification
Cardiopulmonary exercise ; echocardiographic assessment ; myocardial ; ventricular filling
speckle tracking echocardiography ; ste ; biVP ; ventricular pressure overload ;RVPO
atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
coronary revascularization ; hemodynamically
obesity ; diabetes mellitus ; metabolic risk factors ; heart failure ; preserved ejection fraction
sex ; EF ; bNP ; HF ; bNP ; sex ; EF
perk inhibition ; sCN5a ; kv4.3 mRNA ; mRNA ; na+ channel mRNA splice
LVEF ; long-term mortality ; acute decompensated HF
Mena expression ; HF ; mena ; cardiac pathophysiology
salt loading ; uninephrectomy ; ANG II infusion mouse ; cardiac function ; mice ; HF
echocardiographic score ; LV reverse remodeling
atrial fibrillation ;AF ; heart failure ;HF ; stroke ; anticoagulation
HR reduction
bottleneck stent ; myocardial infarction ; antiplatelet medication
ANS ; LV ; fractional shortening ; lung weight
Fontan failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio
systolic heart failure ; spironolactone
dysfunction ; rad variant ;Q66p ; congestive heart failure
implantation ; programmed cell death ; degs
atrial fibrillation ; implantation ; atrial fibrillation ; Stroke prevention Trial

RECENT FINDINGs ; intestinal morphology ; permeability ; absorption function ; CHF
anaerobic metabolism ; respiratory
ARNI ; cardiovascular mortality ; hospitalization ; heart failure
myocardial DD ; muscle strip stiffness ; titin hypophosphorylation
quadriceps force
cardiac hypertrophy ; nucleolin
idiopathic dilated cardiomyopathy
high-volume physicians ; readmission
NP ; POc ; NPs
benefits ; controlled randomized trials
Kansas City Cardiomyopathy Questionnaire ; kccq ; HF ; EF ; HFpEF
annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; ventricular contractile
biventricular support ; HeartMate ; lVAD ; CentriMag right ventricular assist device ; radVAD
Blood pressure ; arm cuff ; stroke volume ; v ; ejection fraction ; end-diastolic volume ; echocardiography
fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; trichrome blue
Caucasian ; sNP rs10927887 ; Ka renal chloride channel gene ;CLCNKA
HF
contractile function ; LV dilatation ; LV ; end-diastolic pressure ;wall stress ; lung weight
NT-probNP ; plasma ; dyspnea ; left ventricular dysfunction ; ed
pathological remodelling ; heart ; cardiac hypertrophy ; HF ; fibrosis ; inflammation
HF-ACtion cohort ; hgb ; baseline HRQoL ; kccq
Circulating progenitor cells ; cPCs ; endothelial repair ; cardiovascular diseases
ventricular ;RV ; patients ; advanced heart failure ;HF
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; emo ; renal function
American College of Cardiology ;American Heart Association ; RAS
functional MS ; valve plasty ; degenerative MR ; LV
EO-cFUs ; CD34 ;vegFR2 ; cells ; mortality
implantable cardioverter-defibrillator deactivation ; heart failure
functional MS ; valve plasty ; annular size reduction ; degenerative MR ; LV
Frailty ; heart failure ;HF ; biological phenotype
LV remodeling ; diastolic properties ; XO inhibition
SDQT ; HFVT ; HFVT ; hnm group ; fixed-rate atrial pacing

diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
bNP ; inhospital mortality
temps-dependent analysis ; IEs ; cRT-d ; heart failure
expenditure ; health per capita ; gross national income ; HF ; LA
bt ; DT ; coût-effectiveness ; bt
af ; pharmaceuticals ; hff
blood pressure control ; lipid-lowering therapy ; smoking cessation ; RAS
coût-effectiveness
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
implantable cardioverter-defibrillators ;ICds ; cardiac resynchronization therapy ; cRT
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; remodeling in heart failure
DASh ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
HFpEF ; echo-Doppler cardiography ; invasive haemodynamic assessment
RAS- ; β-blocker uptitrations ; hFrEF ; HFpEF
exercise-induced PASp ; hg ; PASp
skeletal muscle sarcomere structure ; heart failure ; diabetes ; epicatechin-rich cocoa
Physician volume ; patients ; medically managed diseases ; HF
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
eplerenone ; HF-ref ; hyperkalemia ; wRF
mitochondrial complex V activity ; aac ; phosphocreatine ; ATP
sst2/low-dose BB ; sst2/high-dose ; cardiovascular events
frail ; biological
QRs morphology ; cardiac resynchronization therapy ; cRT
hff ; cardiac event
RM ; implants ; heart failure
acute heart failure ; aHF
embryonic gene programs ; pathological heart disease ; transcription factors
md
LBBB ; implantable cardioverter defibrillator-CRT
heart rate ;HR ; ivabradine ; patients ; systolic heart failure
cardiovascular death ; stroke ; heart failure ; myocardial infarction
heart failure ; hypertension ; mitral regurgitation ; mitral stenosis ; heart failure
Cardiac-resynchronization therapy ; cRT ; morbidity ; mortality ; chronic systolic heart failure
perk activation destabilized sCN5a ; kv4.3 channel mRNAs ; transient receptor potential cation channel m7 ;TRPM7) channel mRNA
implantable cardioverter-defibrillator ; Heart Function Clinic ; University Health Network ;Toronto
Exercise-induced PASp ; pulmonary hypertension ; ventricular contractile reserve
MI ; metoprolol ; plasma norepinephrine ; dopamine ; epinephrine
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
ste2 ; cardioprotective signaling ; myocardium ; biomarker in heart failure ;HF
Cardiovascular Outcomes ; Renal Atherosclerotic Lesions ;CORAL ; stenting ; RAS
mortality ; heart failure ;HF ; implantable cardioverter defibrillators ;ICds
therapeutic left-to-right interatrial shunting ; heart failure ; ejection fraction
Mediterranean ; Dietary Approaches ; Stop Hypertension ;DASh ; mortality ; postmenopausal women ; HF
multiparametric echocardiographic score ; reverse remodeling ; cRT
Yorkshire swine ; implanted ; pacemakers ; ventricularly paced ; heart failure
renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
HF ; HF ; HF epidemiology ; SH ; cd ; rheumatic fever
mortality ; readmissions ; costs ; patient ; physician ; hospital
caloric restriction ;diet ; aerobic exercise training ;exercise ; exercise capacity ; QOL ; obese ; hff
chronic heart failure ;HF ; hemodynamic disorder ; syndrome ; dysfunction ; interconnected molecular pathways
medications ; heart failure ; ejection fraction
HFpEF ; diastolic filling time ; heart rate
mice ; cardiac myocyte-specific Mena overexpression ; tgtetMena ; cardiac pathology
antiplatelet agents ; anticoagulants
international Right Heart Foundation ; defects ; syndrome of right heart failure
POc ; NP
LBBB ; QRs ; implantable cardioverter defibrillator-CRT
echocardiography ; cardiac diameters ; cardiac function ; b-treated
MEDLINE ; EMBAse ; PsycINFO
life ; functional capacity
urban academic medical center
systolic HF ; cXL-1020 ; left ; right heart filling pressures ; systemic vascular resistance ; cardiac ; stroke
therapeutic strategy ; AF ; heart failure ; financier burden
body weight ; FM ;ff ;cc
r
ventricular ejection fraction ; left ventricular diastolic end diameter
eccentric ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
ventricular ejection fraction ; heart failure ; preserved ejection fraction ;HFpEF
β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; failing heart
cardiac hypertrophy secondary to pressure-overload ; abdominal aortic constriction ; aac
hgb ; kccq ; hgb ; HRQoL
patients ; heart failure ; hospital discharge
Fontan failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sVR ; cardiac index
myofiber dynamics ; myofiber shortening ; emd ; dyssynchronous HF
ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
truncated na+ channels ; unfolded protein response ; uPR ; electric remodeling ; HF
intermacs ; interagency Registry for Mechanically Assisted Circulatory Support
allopurinol ; LV contractile function ; efficiency ; XO-mediated ROS ; myofilament
implantg techniques ; systolic function ; HFpEF ; long axis function
physicians ; patients ; advanced heart failure
HF ; multivariate-adjusted odds ratio ; 28-day mortality ; hazard ratio
AAs ; HF ; hyperkalemia ; hypokalemia ; spironolactone
g-protein-coupled receptor kinase-2
NT-probNP
sCN5a ; angII ; hypoxia ; uPR ; downregulation
implant
bNP ; diastolic dysfunction
therapy ; comorbidities
Medicare hospital claims ; Medicare ; post-acute care transfer policy
heart failure ; refill compliance ; etidronate ; alendronate
metabolic exercise ; cardiac ; kidney index score
men ; physique activity ; cRF ; HF mortality
ET ; HDL-mediated protective effects ; molecular pathways ; chronic heart failure ;CHf
dopamine ; nesiritide ; decongestion ; renal function
English language ; anemia ; iron deficiency ; MEDLINE ; cochrane Library
kccq ; HFpEF ; cronbach
implantable cardioverter defibrillator-CRT ;LBBB ; QRs duration

alendronate- etidronate- ; raloxifene-tre
Chemotherapy ; trastuzumab ; CHF ; international Classification of Diseases ; healthcare Common Procedure codes
contemporary heart failure ;HF ; HF ; ventricular ejection fraction ;LVEF
hART ; HFpEF ; HF ; HF ; reduced ejection fraction ;HFrEF
conscious ; hz ; contractility ; end-systolic elastance ; venoarterial dilation
bone morphogenetic protein ; rRNA transcription ; heterochromatic chromatin
actin cytoskeleton ; mitochondrial function ; intermediate metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
resistin ; anthracycline-induced cardiotoxicity ; heart failure
extracellular matrix ; left ventricular biopsies ; tissueFAXs technology correlated
systolic HF ; Danish Heart Failure database ; ESRD ; Danish Registry on Dialysis
ventricular assist devices ; lVADs ; patients ; advanced heart failure ; pump dysfunction ; pump replacement
ST2 ; amino-terminal pro-B-type natriuretic peptide
biventricular pacing ; biVP ; cardiac output ;co ; cardiac surgery
magnetically levitated lVAS ; mortality risk ; Seattle Heart Failure Model-predicted survival
New York Heart Association ;NYha ; chronic heart failure ; reduced ejection fraction ; Canadian special access programme
AlphaLISa immunoassays ; antibodies ; NT-probNP
creatinine ; bNP ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
expression ; mistargeting ; rad ; q66p ; RGK protein ; efficacy
Myocyte hypertrophy ; heart failure ; gene expression
hospitals
biomedical treatment ; CHm ; biomedical treatment ; dCM ; heart failure
sst2/high-dose BB ; sst2 ; b ; cardiovascular event
neurohormones ; adipokines ;cc ; progressive loss ; fat free mass ;FFm ; fat mass ;FM
cardiac plasma membrane ; s1PR1 ; deleterious β1AR overstimulation ; heart failure
Sprague-Dawley rats ; sham ; aCF ; allopurinol
myocardial collagen ; myocardial delayed imaging
saxagliptin ; sitagliptin
catheter ablation ; AF ; compensated hff ; left ventricular ;LV ; ejection fraction
BB therapy ; patients ; chronic heart failure
crte ; hazard ratio
ESRD ; outpatients ; systolic HF ; eGFR
passage ; length-force relationship ; RV ; LV dysfunction
TUnel ; apoptotic cells ; TUnel-positive cells
hno donor ; myocardial function ; HF
biventricular support ; implanted
transitions of care ; congestive heart failure ; non-urbanized Midwestern state ; South dakota
cardiomyocytes ; humoral stimuli ; myocardium
implantation ; MT
implantation ; LV assist device implantation ; heart failure
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation ; creatine kinase activity
intraclass correlation coefficient ;ICc ; kappa coefficient ; change ; mdc
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
race ; exercise training ; chronic heart failure ; Heart Failure ; controlled Trial Investigating Outcomes ; Exercise TraiNing ;HF-ACtion
Swedish national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; caBG
heart failure ; preserved ejection fraction ; hff ; heart failure ; overweight ; obese
Peritoneal dialysis ;PD ; diuretic resistant volume overload ; heart failure ;HF
Renal dysfunction ; heart failure ;HF ; dysfunction ; end-stage renal disease ;ESRD
echocardiographic score ; LV reverse remodeling ; LV end-systolic volume
Peripheral artery disease ;PAD ; heart failure ;HF ; HF ;PAD
heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia
peripheral muscle pump ; cardiac filling ; subpulmonary ventricle ; Fontan circulation
biological phenotype ; deficit index ; medical records
SDQT ; HFVT ; hNorm ; β-adrenoceptor blockade ; esmolol
Cardiology practices ; national Cardiovascular Disease Registry practice Innovation ; Clinical Excellence registry
sts HH ; TM ; medical support ; all-cause mortality ; discharged patients ; heart failure
surgically induced myocardial infarction ; heart failure ; bisoprolol ; vehicle
transitions of care
CHF ; cardiac explant c-Kit
atropine ; cardiac vagal tone ; CHF-DNx ; CHF-INv
hno donor ; cXL-1020) myoctyes ; intact hearts ; heart failure ;HF
drug-free
ms ; subvalvular ; dynamic ; annular MS ; fixed ring size
race ; chronic heart failure ;HF ; exercise
capillary ; coronary perfusion ; b-treated ; ad-flk rats ; b-treated ; ad-c rats
physician volume ; mortality ; internists ; cardiologists
shuttle walk test ; body mass ; hand grip strength
protocol-driven POC ; NP ; consultation ; ED ; throughput ; disposition ; at-risk patients
heart failure ; CHARM programme ;Candesartan in Heart Failure ; Mortality ; Morbidity
Troponin ; N-terminal pro-B-type natriuretic peptide ; biomarker ; heart failure risk ; atherosclerosis risk
interatrial shunting ; patients ; heart failure ; ejection fraction
bmi ; heart rate ; rhythm ; lying ; standing blood pressure ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance
aldosterone antagonist therapy ; chronic advanced heart failure ; post-myocardial infarction heart failure
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin cardiotoxicity
heart failure ; left ventricular ejection ; spironolactone ; Kaiser Permanente Northern California
renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure
mis ; septum ;systolic ; thickness ; LV ; posterior wall thickness ; LV internal diameter ; metoprolol
American College of Physicians ; aCP ; anemia ; iron deficiency ; heart disease
hff ; caloric restriction ; aerobic exercise ; VO2
économique Analysis ; Patient Management Interventions ; Heart Failure Cost-Effectiveness Model ; coût-effectiveness ; disease management ; heart failure
HF registry ; HF ; EF ; HFpEF
BAT ; N-terminal pro-brain natriuretic peptide ; HF
HR variability ; mortality ; AMI ; CHF ;LV dysfunction
cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression
cardiac transplant ;ECCT ; transplant pool ; donors ; transplant
pediatric Fontan ;PF
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
Lancet ; anoop Shah ; air pollution ; heart failure
anemia ; HF ; health-related quality of life ;HRQoL ; HF
cell therapy ; chronic heart failure ;CHf ; explant-derived progenitor cells
mRI-based models ; dyssynchronous nonfailing ; HF canine electromechanics
RV failure ; chronic pulmonary arterial hypertension ;PAh ; acute pulmonary embolism
RV failure ; pulmonary embolism ; mortality
serum resistin ; anthracycline-containing chemotherapy ; cardiotoxicity
sst2 ; b ; cardiovascular event
rad Q66p ; cardiomyopathy
ventricular structure ; geometry ; fiber ;sheet orientation ; handling ; slowed conduction ; wall stiffness
SDQT-to-SDRR ratio ; HFVT ; hnm
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; ventricular ejection fractions
Exercise ; Medical Therapies ; Cardiac Function ; Shortness of Breath ; Lung Congestion
electrical stimulation ; peripheral muscles ; endothelial function ; heart failure ; ventricular ejection fraction
tachycardic response ; methylatropine ; vagal tone ; bradycardic response ; propranolol
cardiac resynchronization therapy ; cRT ; mild heart failure ;HF ; QRs prolongation ; ejection fraction ;EF
Fractional flow reserve ; positron emission tomography imaging ; ischemia ; bottleneck stenting ; left ventricle ; LAD
mitochondrial oxidative phosphorylation ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
spironolactone ; death ; hyperkalemia ; acute kidney injury
mortality ; cardiovascular mortality ;HF hospitalization ; cox models
Neprilysin inhibitors ; natriuretic peptide system ; atrial natriuretic peptide ; b-type natriuretic peptide
TAPse ; PASp ; nonsurvivors ; hFrEF ; HFpEF
HF-ACtion ; HF ; HF ; ejection fraction
proteins ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac development
NT-probNP ; mortality ; acute HF
haematopoietique cell transplantation ; hCT ; congestive heart failure ;CHf ; hCT ; anthracyclines
cardioprotective effect ; nicorandil ; hemodynamic alterations ; mitochondrial dysfunction ; doxorubicin
in vivo inhibition ; mir-25 ; cardiac dysfunction ; murine myocardium ; heart failure
Chinese herbal medicine ;CHm ; dilated cardiomyopathy ;DCm ; heart failure
hypertension ; hg ; diabetes mellitus ; systolic ; diastolic murmurs
hypoalbuminemia ; albumin
electrical activation ; dyssynchronous heart failure ;HF ; electromechanical behavior ; heart
patients ; advanced heart failure ;heart team ; cardiologists ; cardiovascular surgeons
Baroreflex sensitivity ; time domain heart rate variability ;HRV ; CHF-INV ; sham-INv ; sham-inv ; renal DNx
bisphosphonates ; alendronate ; etidronate ; heart failure
nurse ; cognitive impairment ; physician ; discharge ; elderly patients ; heart failure
carvedilol ; β-blocker ; β-blocker metoprolol ; thromboembolic events ; heart failure
cardiac transplant survival ; ECCT
HF ; AMI ; pna ; mortality
patients ; heart failure ;HF ; HF
implanting ; arrhythmia substrate ; AMI ; HR variability
doxorubicin-induced cardiotoxicity ; Hum-Retn mice ; littermate ; human resistin ; retn
hypertension ; compensated HFPEF ; DASh ; sRD ;target sodium ; kcal
emd ; dyssynchronous HF
diastolic dysfunction ; pathophysiology ; HFpEF ; non-diastolic abnormalities ; cardiovascular
ejection fraction ; cardiac index ; inotropes ; inotrope-dependent
lipoprotein ;HDl ; endothelial-protective effects ; endothelial cell ;EC ; nitric oxide
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
degs ; non-ischemic ; ischemic heart failure ; healthy control ; heart failure
insulin resistance ; diabetes ; insulin receptor substrates ;IRs1 ; iRS2 ; insulin-signaling ; cellular metabolism
admission to discharge ; hospitalized older adults ; heart failure ;HF ; Nursing Outcomes Classification ;NOc
8-fluo-cAMP binding ; phosphomimic ; ser77 ; ser83 mutant ; RIα ; double mutant ; WT RIα
preoperative albumin ; mortality ; lVAD implantation
systolic heart failure ; QRs ; cRT ; hospitalization ; heart failure
cox regression models ; propensity score decile ; oral glucocorticoid ; HF hospitalisations ; loop diuretics
fonctional electrical stimulation ; fes ; emotional stress ; endothelial function ; chronic heart failure ; impaired systolic function
Dialysis ;HF
bleeding ; driveline infection ; gastrointestinal bleeding ; debilitating stroke
Beta blockers ; readmissions in heart failure ; ejection fraction ;HFrEF ; heart rate ;HR
dyssynchronous HF ; electromechanical delay ; emd ; myocyte depolarization ; myofiber
QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ;RAFt
biomarker ; biomarker-guided clinical trial ; multimarker-based strategy
abnormal liver ; nodularity
transplant ineligible patients ; PD ; HF volume management ; pre-PD initiation
Frailty ; biological phenotype ; weak grip ; physical exhaustion ; slowness ; activity ; unintentional weight
cRT-d ; IE ; IC ; cRT-d ; IEs
eds ; heart failure ; low-volume ED
acute right heart failure ; therapy refractory cardiogenic shock ; heart ; extra corporeal membrane oxygenation ; emo ; cPR ; ICU
right atrial myxoma ; massive embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
heart disease ; HF ; surgical palliation
heart magnetic resonance imaging ; chelation choices ; patient compliance ; heart failure ; arrhythmias
ejection fraction ;EF ; pre-PD ; NYHA class IIIb ; ventricular dysfunction
cPCs ; early-outgrowth colony-forming units ;EO-cFUs ; circulating CD34 ; vEGFR2 ; CD133
Gene expression ; Bax ; bcl-2 mRNA expression ; heart failure ; bcl-2/Bax
nitroxyl ; hno ; Angeli ; salt ; inotropic ; lusitropic ; vasodilator effects ; cAMP
therapy ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ;AF
coût-effectiveness ; continuous-flow lVADs ; heartMate II ; hm ; hm ; HeartWare ; bt ; DT
EF ; blinded core laboratory
skeletal muscle mass ; appendicular lean mass index
DASh ; mortality ; HF ; Mediterranean
Quality of life ; all-cause mortality
bNP ; inhospital mortality
cardiovascular diseases ; heart failure ;HF
heart failure ; left ventricular systolic dysfunction ; BB
CLCNKA polymorphism ; heart failure ; glomerular filtration rate ; RENASTUR
ST2 ; functional capacity ; well-treated ; ambulatory patients ; HF
cardiac VEGF expression ; Akt ; endothelial NO synthase activation ; drug-untreated failing hearts
cardiomyocytes ; jq1 ; drug abrogated ; phenylephrine-induced genes
exercise-induced PASp ; right ventricular contractile reserve
Gene expression profile ; gse9128 ; Gene Expression Omnibus ; non-ischemic heart failure ; ischemic
cardiac insulin-resistance ; aac ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
DASh ; sRD brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular ; echocardiographic
Psychosocial Factors ; Exercise Adherence ; Heart Failure Patients ; Heart Failure ; controlled Trial Investigation ; Exercise Training ;HF-ACtion
coronary angiography ; systolic HF ; unclear etiology
arterial elastance ; end-systolic elastance ; ees ; ventricular-arterial coupling ; ees
rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device
angiotensin II ; angII ; hypoxia ; activators ; abnormal SCN5a mRNA splicing
HF ; reduced ejection fraction ;HFrEF ; HF ; HF ; preserved ejection fraction ; hpEF
extracorporeal life support ; bridging therapy ; acute ischemic right heart failure ; refractory cardiogenic shock
heart failure ; left ventricular ejection fraction ; Fes ; endothelial function ; HFpEF
expenditures ; noncardiovascular diagnoses ; implantable cardiac arrhythmia devices ; noncardiovascular drugs
intubation
raloxifene ; cardiovascular failure
hearts ; tgtetMena mice ; wild-type littermates ; heart mass ; transgenic mice
hfrf ; respiratory gas
drugs ; heart failure ; biomedical reasons
Wasting ; fat ; lean mass ; fat loss ; catabolism ; adipose tissue ; cardioprotective ; HF
hearts ; fish lacking nucleolin ; chamber patterning ; functional deficits ; cardiac looping ; myocyte differentiation
black race ; HF ; modifiable risk factors ; exercise performance ; HF ; mortality
acute myocardial infarction ; congestive heart failure
cardiomyocytes ; Hum-retn mice ; doxorubicin ; hretn ;human resistin ; mRNA ; protein expression
lVADs ; CF devices ; HeartMate II devices ; Thoratec Corp ; Pleasanton ; Calif ; hVAD ; hVAD devices ; HeartWare intl ; intl ; Framingham ; Mass
FM ; plasma NPs ; adiponectin ; FM ;ff ; NPs ; adiponectin
sympathetic tone ; parasympathetic tone ; heart rate ; metoprolol ; atropine
EH ; HFpEF ; pathophysiologically ; HF ; hff therapy
HF ; immunoreactive NT-probNP ; c-terminally truncated fragments ; NT-probNP
beat-to-beat QT interval ; surface ECGs ; atrial pacing ; esmolol ; isoprenaline ; atropine infusion

power spectral analysis ; low-frequency ;high-frequency ;LF ;HF ; CHF-inv ; sham-inv ; sham ; DNx
contractility ; ventricular-arterial coupling ; ivabradine-tre
hospital quality improvement
N-terminal pro-B-type natriuretic peptide ;NT-probNP ; misdiagnosis ; heart failure ;HF
cardiac magnetic resonance ; hfEF ; biomarker ; hff
h-action ; left ventricular ejection fraction ; New York Heart Association ; HF
myocardial DD ; collagen deposition ; titin modification ; obese ; diabetic zSF1 rats ; heart failure ; ejection fraction
cardiac tissue ; mice ; TAC- ; sham-operated ; jq1 ; vehicle ; BET inhibition ; pathological cardiac expression programme
cox-proportional hazard models ; negative binomial regression models
Systolic blood pressure ; left ventricular ;LV ; hypertrophy ; AT ; AN ; AS ; ANS
conditional gene-targeted Hand2 mice ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene program
NT-probNP ; ED ; acute HF
Peak oxygen consumption ;VO2max ; resting HR
heart failure ; noncardiac ; cardiac transplant
frailty ; Health ABC Short Physical Performance Battery ; hABC Battery ; Gill index ; HF
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; abrogate pathological gene expression ; HF progression
clinical prediction rule ; CAD ; angiography ; systolic HF
load-corrected chronotropic response ; heart rate
hospital ; gastrointestinal bleeding ; ventricular tachycardia storm ; terminal heart failure
catheter-based percutaneous revascularization ; angioplasty ; stenting
HF ; t2d ; ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
HF ; QRs prolongation ; LVEF ; crte ; reverse remodeling ; clinical benefit ; LV
RV ; lVAD insertion ; cardiogenic shock ; myocardial infarction ; chronic decompensated heart failure

non-frail ; h ; severe frailty ; h ; Gill index ; HF
HF ; AMI ; odds ratio
Chronic heart failure ;CHf ; multisystem disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
β-AR stimulation ; catecholamine infusions ; pde2 expression ; cAMP hydrolytic activity ; blunted cardiac β-AR responsiveness
chronic PAH ; RV decompensation ; pharmacologic therapies ; RV failure management ; pAH
zSF1 ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular DD
Xanthine oxidase ;XO ; rat ; left ventricular ;LV ; myocytes ; volume overload ;VO ; mitral regurgitation ; aortocaval fistula ; acf
free-breathing pulse sequence ; myocardial t1 changes ; swine model ; tachycardia-induced heart failure
PF cohort ; New York Heart Association
comanagement ; medication
physicians ; mortality ; low-volume physicians ; low-volume hospitals
Western Australian ; administrative health ; HF ; AMI
conditions ; Turkey
eds ; responsable diagnosis ; heart failure
nursing-sensitive ; science ; HF
miRNAs ; RNAs ; RNAs ; binding ; messenger RNA ; degradation ; repression
HFpEF ; ivabradine
Cardiac c-Kit ; cardiac explant-derived cells ; cardiac ; implant-derived cells ; cardiac functions ; myocardial infarction
NPs ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
pathophysiology ; HF ; medical management ; pathophysiologic
heart failure ;HF ; acute myocardial infarction ;AMI ; pneumonia ; pna
mortality ; healthcare utilization ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
inhibitor ; jq1 ; BETs ; chromatin ; RNA polymerase II ;Pol II
catheter ablation ; atrial fibrillation ;AF ; heart failure ; preserved ejection fraction ; hff
heart failure ; preserved ejection fraction ;HFpEF ; patients ; health status
cox proportional hazards regression ; i ; acute coronary syndromes ; coronary interventions
cyclic adenosine monophosphate ; cAMP ; augmented cyclic guanosine monophosphate ; cgmp ; failing hearts
RA ; methotrexate ; tNF antagonist ; non-biological disease modifying antirheumatic drug ;nbDMARD
intestinal dysfunction ; disturbed intestinal barrier ; chronic inflammatory state ; catabolic/anabolic imbalance ; cardiac cachexia ; CHF
ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
sphingosine-1-phosphate receptor ; s1PR ; β1-adrenergic receptor ;β1AR ; g-protein-coupled receptors ; heart
septal ; PCWP
atrial fibrillation ; carvedilol ; metoprolol
Bradycardia induced ; metoprolol ; cardiac sympathetic tone ; CHF-INv rabbits ; sham-INv ; CHF-DNx
Nordic walking ; standard cardiac rehabilitation ; functional capacity ; heart failure
cPG-recommended pharmacological treatment ; device consideration ; self-care education ; left ventricular
grs ; LVEF ; sa ; CV ; echocardiographic systolic parameters ; AF
ERC ; DAPc protein ; sarcomeric microstructure ; Skm ; myofibre regeneration
signalling cascades ; microRNAs ; bHLh transcription factor Hand2 ; postnatal mammalian myocardium ; embryonic gene programs ; heart failure
rad ; q66p ; inhibitory actions ; rad ; cav1.2 ; cav1.3 ; l-type channel isoforms ; heart
EF ; LCx ; LAD ; LAD ; stenting ; infarcted left ventricle ; LCx ; LAD
EH ; LV compliance ; hz ;LV end-diastolic volume ; hg ; coefficient ; ml
mva ; surgical ring implantation ; leaflet motion ; leaflet resection ; edge-to-edge anastomosis
hART ; New York Heart Association ;NYHA ; HF ; self-management counseling ; death ; HF
cardiac function ; echocardiography ; diastolic dysfunction ; e ; ejection fraction
BET family bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; HF
blood transfusions ; iron ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
guidelines ; Grade
HF
vent circulatory failure ; mécanismes of disease ; right heart
influx ; l-type voltage-gated ; ventricular action ; trigger ; excitation-contraction ;EC ; coupling ; myocardium
ivabradine ; ventricular filling ; heart failure ; preserved ejection fraction ;HFpEF
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes
bNP ; glomerular filtration rate ; hypertension ; transmitral E-wave ; diastolic mitral annular velocity
AT1 receptors ; neprilysin blocks renin-angiotensin-aldosteron ;RAS ; vasodilatory ; diuretic peptides
β-blockade ; cAMP-dependent protein kinase ; pKA ; β-adrenergic receptor activation
erythropoiesis-stimulating agent therapy ; harms ; venous thromboembolism
black race ; mortality ;hazard ratio ; cardiovascular mortality ;HF
chronic myocardial ischemia ; stent ; polytetrafluoroethylene tube
clinical ; genetic ; CHF predictive model ; curve ; genetic ; auc ; clinical
implantation ; oxygen uptake ; metabolic exercise ; cardiac ; kidney index ; HF
heart failure ;HF ; tumor necrosis factor ;TNf ; tNF antagonists ; HF
Centers for Medicare and Medicaid services ; cms ; hospital quality of care outcomes ; mortality ; readmission rates ; penalties
cox proportional hazard models ; temps-dependent covariates ; follow-up ; physician ; discharge
techniques regression analysis ; severe CAD ; diameter stenosis ; left main ; 3-vessel CAD ; figure ; CAD ; proximal left descending artery
signal transduction cascade ; transcription factors ; cardiomyocytes ; transcription factors ; epigenetic changes ; chromatin structure
hff ; sodium-restricted DASh ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; ventricular dilatation
aldactone Evaluation Study ; chronic advanced heart failure ; aldosterone antagonist ; spironolactone ; mortality
heart failure ; acute myocardial infarction
CHF ; hCT ; polymorphisms ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication
pathophysiological origin
lVAD ; albumin ; hypoalbuminemia
creatinine ;hazard ratio ; dL
glomerular filtration
scientific literature ; h II ; HeartWare patients ; économique evaluations ;HM II
dopamine ; nesiritide ; renal function ; acute heart failure ; renal dysfunction
HR variability/turbulence ; implantation ; cardiac patients
implantation ; lVAD therapy ; implantation eligibility status ; device ; bt ; DT ; medical therapy
radial artery tonometry ; PH ; ICU
magnetically levitated centrifugal-flow chronic lVAS
eRK ; signalosome complex ; scaffold protein ; kinases ; sequential phosphorylation
Medicare coverage ; stage I-III breast cancer ; chemotherapy ; sEER-Medicare ; Texas Cancer Registry-Medicare
ejection fraction ; b-type natriuretic peptide ; heart failure ; inhospital outcomes ; guideline-Heart Failure Registry
cardiomyocytes ; pde2 activity ; cgMP synthesis ; nitric oxide ; pde2 inhibition ; β-AR responsiveness
l-dKO mice ; cardiac IRS1 ; iRS2 proteins ; heart failure ; impaired cardiac energy metabolism ; protein kinase
ECs ; HDL ; phosphorylation ; eNOS-Ser ; eNOS-Thr ; PKc-βII-Ser
PASp ; walking distance ; kilogram
RCTs ; sts ; h ; h ; hm ; TM ; sts ; TM
mouse ventricular myocytes ; sarcomere
administrative databases ; province of Alberta ; discharged alive ; hospital ; heart failure
animals ; heart failure ; myocardial collagen ; tissue
crte ; time to death ; HF hospitalization ;hazard ratio ; LVEF
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; s1PR ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; s1PR1 cardiac gene therapy
relative risk ;RR ; heart failure ; bisphophonates ; crude RR
Medicare fee-for-service beneficiaries ; Centers for Medicare ; Medicaid services ; propensity-score
physician adherence ; guideline recommendations ; heart failure ; Clinical Practice Guideline ;CPg ; heart failure ;HF
nicorandil ; doxorubicin-induced heart failure ; rats ; hemodynamic perturbations ; mitochondrial dysfunction ; antitumor activity
kccq ; New York Heart Association class ; HFpEF ; HF ; HF ; EF
Rhythm control therapy ; af ; atrial structure ; rhythm ; delayed rhythm control ; rate control
acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic therapy
HF ; body composition ;skinfold thickness ; dual-energy X-ray absorptiometry ; echocardiography ; blood testing
implantment ; heart failure
aCP ; restrictive red blood cell transfusion ;trigger hemoglobin ; hemoglobin ; coronary heart disease
hospitals ; heart failure ;HF ; conditions ; acute myocardial infarction ; pneumonia
implanted left-to-right interatrial shunt ; haemodynamic outcomes ; heart failure ; ejection fraction
ventricular-pulmonary arterial coupling ;pulmonary vascular resistance ; right ventricular ejection fraction
ventricular assist devices ; lVADs ; chronic end-stage heart failure ;bridge to transplantation ; bt ; transplant-ineligible patients ; destination therapy
Caloric restriction ; Aerobic Exercise Training ; Peak oxygen Consumption ; Quality of Life ; Heart Failure ; Preserved ejection Fraction
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-crte ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
Oral glucocorticoids ; HF
HR ; ivabradine group ; Ea ; TAC
carvedilol ; inappropriate therapy ; metoprolol
CHm ; adjunctive treatment ; dCM ; heart failure
testosterone supplementation ; exercise rehabilitation
VO2 ; change ; lean body mass ; change ; thigh muscle ;intermuscular fat ratio
guidelines-Heart Failure ; hf
économique Analysis ; Patient Management Interventions ; Heart Failure Cost-Effectiveness Model ; coût-effectiveness ; disease management programs in heart failure
HFPSI ; risk of death ; medical hospitalization ; HF clinic outpatients ; HF resources ; health systems
cardiac insulin-resistance ; mitochondrial oxidative metabolism ; metabolic changes ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
cox model ; gain ; PASp ; figure
pathophysiology ; heart failure ; preserved ejection fraction ; hff ; myocardial extracellular matrix accumulation
annular size reduction ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ;LV
breathing control ; cardiac arrest ; pulseless ventricular fibrillation ;PVf ; implanted cardioverter-defibrillator device
rad ; rem ; rem2 ; rad ; Gem ;Kir ; monomeric g proteins ; ventricular action ; EC coupling gain ; cardiac l-type channel activity
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; HF ; myocardial infarction
cardiac sympathetic activity ; i-meta-iodobenzylguanidine ; i-miBG ; β-blocker
Swedish web-system ; evidence-based care ; Heart disease ; Recommended Therapies registry ; caBG
LVEF ; reverse remodeling parameters ; time to death ; HF
brain natriuretic peptide ; bNP ; bNP ; bNP ; bNP
coprimary end points ; cumulative urine volume ; decongestion end point ; change in serum cystatin C ; enrollment ;renal function end point
tAPse ;longitudinal RV fiber shortening ; PASp ;force generated ; RV ; in vivo RV length-force
pde superfamily ; pde2 ; cgmp ; cAMP hydrolysis ; cgmp ; cAMP signaling
n-terminal proBNP ;NT-probNP ; midregional proANp ;MR-proanp ; adiponectin ; CHF ; bmi ; FM
re-hospitalization
mitochondrial-targeted antioxidant ; protective peptides ; Szeto-Schiller ;SS ; SS20 ; cardiac function ; proteomic remodeling ; signaling pathways
cardiac arrest ; cardiopulmonary resuscitation ; cPR ; posterior wall infarction ; cardiac centre
hyperkalemia ; mineralocorticoid receptor antagonists ; race ; mineralocorticoid receptor antagonists ; heart failure ;HF
aCP ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; second-generation sulfonylureas ; long-acting insulin products
uPR ; sCN5a ; ventricular systolic HF ; implanted pluripotent stem cell-derived cardiomyocytes ;hiPSc-CMs
ambulatory patients ; heart failure ;HF ; ejection fraction ;rEF ; renin-angiotensin system ;RAS ; β-blockers
cochrane Effective Practice ; organisation of Care Taxonomy
coPD ; CHF ; cRF ; ICC ; kappa coefficients
heart failure ; left ventricular ejection fraction ; aerobic training ; dynamic resistance training ; lower limbs
implantable cardioverter-defibrillator deactivation ; implant ; implant
heart failure ; poor myocardial function ; ventricles
implantable cardioverter-defibrillator deactivation ; implantable implantable cardioverter-defibrillator shocks
global left ventricular longitudinal systolic strain ; grs ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ;AF
mouse rad ; murine ; rad ; rad ; q66p ; l-type currents ; cav1.2 ; cav1.3 ; rad
MI ; hazard ratios ; HF
national Medicare ; patients ; acute care hospital ; HF ; AMI ; pna
cardiovascular events ; sst2 status ; hz ; ms ; metoprolol succinate
ctnt ; NT-probNP ; aRIC HF model ; aucs ; continuous NRIs
HF ; HF ; EF ; HF ; HF ; HF ; MI
EC ; HDL ;NYha-IIIb ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDL
carvedilol ; Willebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
mouse heart failure ;HF ; hypertensive heart disease ; hHD ; pathophysiology ; hHD
sarcoplasmic reticular ;SR ; ca(2+)-uptake ; protein ; SR ; ca(2+)-pump ; phospholamban ; infarcted hearts ; metoprolol
tempsd up ; go ; tug ; patients ; advanced chronic obstructive pulmonary disease ;COPD ; chronic heart failure ;CHf ; chronic renal failure ;CRf
inmuscular testosterone supplementation ; chronic heart failure ;CHf ; low testosterone
HF ; LVEF ; long-term mortality ; LVEF ; long-term mortality
grs ; left ventricular ejection fraction ;LVEF ; systolic mitral annulus velocity ; sa ; CV
heart failure ;HF ; plasma ; b-type natriuretic peptide ; bNP ; ejection fraction ;EF ; HF
RM ; implanted monitoring devices ; medical support ; telephone support ; sts ; human-to-human contact ;HH ; human-to-machine interface ;HM
cox regression ; beta-blockers ; beta-blockers ; antitachycardia pacing ; aTP ; shock therapy
ethically complex situations ; pediatrics ; families ; religious beliefs ; life-sustaining treatment
patient preferences ; priorities ; guideline-recommended medications
coût ; rhythm-control ; rate-control
median age ; women ; median left ventricular ejection fraction ; median egFR ; ml
fit ; unfit ; cRF distribution ; hazard ratios ; fit ; unfit ; obese men
crte ; hazard ratio ; confidence interval
HFPSI ; blood urea nitrogen ; b-type natriuretic peptide ; New York Heart Association class ; diabetes ; atrial fibrillation ;flutter
Medicare Patient Safety Monitoring System ; mpSMS ; adverse event rates ; patients hospitalized ; acute myocardial infarction ; congestive heart failure ; pneumonia ; surgery
CD34+vegFR2+ cells ; functional capacity ; CD34+vegFR2 ; cells ; VO2
implants ; heart failure ; reduced ejection fraction
crude 28-day case-fatality rate ; HF
CHF ; anthracycline exposure ; stem cell source ;allogeneic
tension ;fpassive-sarcomere length relations ; muscle strips ; kcl-KI treatment ; titin ; extracellular matrix ; Fpassive
reversibility ; heart failure ; myocardial infarction ;MI ; β-adrenoceptor blockade ; infarcted rats ; metoprolol
aerobic ; resistance training ; benefits ; exercise capacity ; muscle strength ; cardiac ;NT-probNP ; inflammatory ; i6 ; hsCRp
hospital performance ; all-cause readmission ; aCR ; Potential Preventable Readmission ; pPR ; Centers for Medicare ; Medicaid 30-day readmission ; cMS
congestive heart failure ; ed
rehabilitation ; distance ; walking
arginine vasopressin ; aVP ; physiologic processes ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
implantable defibrillators ; circulatory support ; transplantation ; heart failure
sodium-restricted dietary ; hypertension diet ;DASh ; sRD ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hypertensive HFPEF
rapid ventricular pacing ; Bax ; bcl-2 ; Caspase-3 ; RTq-PCr ; interventricular septum biopsies ; beagle dogs ; heart failure
rats ; hearts ; caspase-3 activity ; phosphocreatine ; adenine nucleotides ; cytochrome c ; bcl2 ; Bax ; caspase
metoprolol ; carvedilol ; sympathetic activity
acute HF ; RELAx-aHF ; ASTRONAUT ; PRONTO ; patient enrollment
Hospitalized HF ; international Classification of Diseases ; Clinical Modification codes ; principal discharge diagnosis
Pulmonary capillary wedge pressure ; hg ; hg ; hg ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
rad ; Q65p ; gating movement ; rad ; wild-type rad ; Q65p ; implantion ; l-type channel inhibition ; RGK proteins
heart failure ; proteomics ; actin cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
aortic insufficiency ;AI ; mechanical circulatory support ; continuous flow ;CF ; left ventricular assist devices ; lVADs ; pulsatile devices
pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; ventricular dysfunction ; HF
discharge
heart failure ; refractory ; terminal heart failure
heart failure discharges ; University of Connecticut health Center
New York Heart association ;NYha ; class II Heart Failure ; eplerenone ; placebo ; standard Heart Failure Medicines ;EMPhaSIS-HF Study
ventricular base ; midpapillary ; apex ; IVc occlusion ; biVP ; ste ; twist ; apical ; basal rotations ; CS ; RS ; synchrony
drugs ; RAas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic studies ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
HF ; HF ; phenylephrine ; haemodynamic stress ; surgical method of transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
Muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan
i-mig cardiac washout ; carvedilol ; metoprolol ; β2-adrenergic receptor haplotype
acute myocardial infarction ;AMI ; heart failure ;HF ; complicating AMI
h-dKO ; ventricular mass ; cardiac apoptosis ; fibrosis ; failure ; Akt ; forkhead box ; impaired cardiac metabolic gene expression ; ATP
bottleneck stent ; proximal left anterior descending ;LAD ; proximal circumflex artery ;LCx ; proximal LCx ; LAD
hospitalized heart failure ; hHF ; dipeptidyl peptidase-4 ; dp-4 ; antihyperglycemic agents
quality improvement database ; multivariable cox modeling ; Heart Failure Patient Severity Index ;HFPSI ; University of Michigan ; hf ; hp ; ue ; hp
pde2 ; cardiomyocytes ; cAMP ; ca2 ; inotropic effect ; acute β-AR stimulation ; basal contractility
ATP ; inappropriate shock therapy
Cardiac resynchronization therapy ; cRT ; dialysis-dependent patients ; heart failure ;HF ; cRT ; dialysis
cardiorespiratory fitness ;CRf ; body mass index ; heart failure ;HF ; cardiovascular risk factors ; HF mortality ; fit ; unfit men
eplerenone ; hyperkalemia ; renal function ; EMPHASIS-HF ; eplerenone in Mild Patients Hospitalization ; survIval Study in Heart Failure
Heart rate ;HR ; cardiac patients ; acute myocardial infarction ;AMI ; congestive heart failure ;CHf ; left ventricular ;LV
neonatal rat ventricular cardiomyocytes ; chronic insulin exposure ; iRS1 ; iRS2 proteins ; insulin action ; cardiac dysfunction ; insulin resistance ; diabetes
ventricular midpapillary ; atrioventricular delay ; avd ; interventricular delay ;VVd ; ste ; circumferential strain ;CS ; radial strain ;RS
New York Heart Association ;NYHA ; HF ; ejection fractions ; chronic stable guideline-directed medical therapy ;GDMT
non-LBBB ; QRs ; hazard ratio
dyssynchronous HF ; myofiber ; septum ; depresses ; myofiber shortening ; stretch rate ; late-activated lateral wall
label-free shotgun proteomics ; global proteomics ; transverse aortic constriction ;TAC-induced heart failure ; signaling pathway changes ; ingenuity pathway
CHF ; transforming growth factor-β ; tGF-β ; epithelial ; mesenchymal transition markers ; pluripotency markers ; shams
pka ; regulatory ;RIiα ; catalytic ; cα ; rIIα ; ser96) ; cα ; phosphorylation ; HF
hf ; left ventricular ejection fraction ; hfpEF ; left ventricular ejection fraction ; RAS- ; β-blocker
g-protein-coupled receptors ; reciprocal regulation ; mouse hearts ; β-adrenergic receptor stimulation ; rat ; postischemic heart failure
concentric remodeling ;CR ; concentric hypertrophy ;CH ; left ventricular ;LV ; remodeling in heart failure ; preserved ejection fraction ;HFpEF ; eccentric hypertrophy ;EH
weight ; diet group ; exercise
RV dysfunction ;hazard ratio ; confidence interval ; CI ; cachexia ;hazard ratio
resting HR ; VO2max
tGF-β inhibition ; c-Kit+ cell ; implantation ; cardiac progenitor function ; cell expansion
NT-probNP ; inflammatory biomarkers ; hsCRp ; il6 ; hsCRp
BETs ; neurohormonally induced heart disease ; jq1 ; phenylephrine-mediated hypertrophy ; cardiomyocytes ; pathological gene induction
BAT ; implantal pro-brain natriuretic peptide ; burden ; heart failure ; GDMT-treated NYHA functional class III HF
p70s6K ; PKc-βII ; HDl ;nyha-IIIb ; malondialdehyde bound ; HDl ;NYha-IIIb ; HDl ;healthy
MLHF ; exercise ; diet
nonpace ; non-DNx ;ham-Innervated ; sham-inv ; nonpace DNx ; hz-DNx ; pace non-DNx ; chf-inv ; pace ; DNx ; hf-DNx
hABC Battery score ; HF risk ; Health ABC HF Model ; hz ; SD ; death
age ; sex ; ejection fraction ; frail ; biological phenotype ; risk of death ; frailty ; deficit index
hemoglobin ; hgb ; HRQoL ; training-induced changes ; HRQoL ; patients in Heart Failure ; controlled Trial Investigating Outcomes of Exercise Training ;HF-ACTION
atrial Fibrillation ; congestive Heart Failure trial ; health care expenditures ; patients ; Québec ; rhythm ; rate-control treatment ; coût-minimization
heart failure ; myocardial ischaemia ; tachy- ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; renal dysfunction
calcineurin/nfat signalling ; miR-25 expression ; helix-loop-helix ; bHLh ; Hand ; diseased human ; mouse myocardium
Exercise time ; PSSS ; btes
NT-probNP
prognostic power ; r-R interval oscillations ; HR variability ; short-term fractal scaling exponent
diastolic filling formalism ; relaxation ;viscoelastic ; passive/stiffness ; doppler mitral inflow velocity ; e-wave
heart failure ;HF ; ventricular tachycardia ;HFVT ; HF ; VT ; hnm
grs ; cox model ; chronic heart failure ; hypertension ; diabetes ; prior stroke score ; glomerular filtration rate ; LVEF ; CV
ventricular assist device support ; ECmo ; extracorporeal membrane oxygenation membrane support ; VAD
ischemic events ;IEs ; ischemic cardiomyopathy ;IC ; cardiac resynchronization therapy ; defibrillator ; crte-d ; device
coût-effectiveness ; heart failure disease management
human resistin in heart failure ; humanized mouse ; murine resistin ; transgenic ; human Retn gene ; hum-retn mice ; basal ; inflammation-stimulated resistin
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers ; β-blockers ; devices
tttMena mice ; cardiac injury ; ejection fraction ; fractional shortening ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; Ambulatory Heart Failure Trial ; implantable cardioverter defibrillator-CRT ; heart failure
heart failure ; Italy ; cfa ; SCHFI ;Self-Care Maintenance ; Self-Care Management ; Self-Care Confidence
mwt ; NYha class ; HFpEF ; hFrEF ; therapy ; hfpEF ; HFpEF
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
Raf-MEK1/2-ERk1/2 scaffold proteins ; adaptive ; maladaptive cardiac remodelling
CHF ; SD testosterone ; testosterone
functional MS ; LV dilatation ; heart failure ;HF ; LV ; functional MS ; HF ; MR ; degenerative mitral valve
New York Heart association class ; kccq ; symptom ; HF ; EF ; HFpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure
c57bl ; ANG II infusion ; uninephrectomy ; ang ; salt loading ;as ; ANG II infusion ; uninephrectomy ; salt loading ;ANS
early transmitral blood flow ; tissue ; doppler ; diastolic mitral annulus ; pulmonary capillary wedge pressure ;PCWP ; decompensated systolic heart failure ;HF
LV ; ejection fraction ; LV ; strain ; strain rate ; systole ; diastolic indices ; LV ; strain rate ; diastole ; early transmitral flow ; sinus rhythm
VO2 ; exercise ; body mass
age- ; sex-adjusted risk ; hazard ratios ; cim ; early-onset HF
AMI ; hospital ; hospital ; odds ; dying
Mass spectrometry ; N- ; c-terminally processed forms ; circulating NT-probNP ; physiological proteolysis ; leu3 ; grly4 ; figure
ctnt ; NT-probNP ; laboratory report ; ctnt ; NT-probNP ; HF
HFpEF ; New York Heart Association class II ; mean ejection fraction
depressed left ventricular ;LV ; pressure ; pressure ; ejection fraction ; fractional shortening ; cardiac output ; LV ; end-diastolic pressure ; mis ; metoprolol
baroreflex Activation Therapy ; Heart Failure ; Reduced ejection Fraction ; carotid baroreflex activation therapy ;BAT ; advanced heart failure ;HF
enrollment
HF ; HF ; raised blood glucose ; obesity ; tobacco ; aging ; systemic hypertension ;SH ; rheumatic fever ; Chagas' disease ; cd
cRF ; normal ; overweight ; obese body mass index
kccq ; HFpEF
egFR ; egFR ; egFR ; uncontrolled hypertension ; diuretics ; temps ; ESRD
myocardial phosphodiesterase-2 ; pde2 ; heart failure ;HF ; pde2-mediated effects ; beta-adrenergic receptor ;β-AR ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm mitochondrial structure ; ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; maisel ; Henry
death ; urgent readmission
mena overexpression ; TTA ; tgtetMena mice ; TAC surgery ; cardiac hypertrophy ; TTA ; tgtetMena ; TAC cardiac functional deterioration
echocardiography ; LV ; end-diastolic volume ; ml ; MR ; mitral valve opening ; mva ; pression gradient ; hg
p ; diuretic refractory severe-end-stage HF
ATP production ; aac ; mitochondrial oxidation ; glucose ; lactate ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York Heart Association class III heart failure ;HF ; left ventricular ejection fraction ; permanent periodic breathing ;PB
implantation ; bottleneck stent ; proximal LAD ; LCx ; porcine model of reversible myocardial ischemia ;open stent ; ischemic heart failure ; stent
potassium ; spironolactone ; AAs ; race
obese ; dSD ; body mass index ; hff
proangiogenic effects ; b ; VEGF pathway ; adenoviral vector ; decoy VEGF receptor ; ad-flk ; adenovirus ; ad-c ; b
surgical treatment ; post-LVAD AI ; aortic valve ; leaflet repair ; bioprosthetic aortic valve replacement ; CF lVAD ; AI
exercise-induced pulmonary artery systolic pressure ;PASp ; stress ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
MEDLINE ; EMBAse ; HEalthSTAR ; cINAHL ; cochrane Library ; Campbell Collaboration ; Joanna Briggs Institute Evidence Based Practice
VA healthcare systems ; systolic heart failure ; β-blocker ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors intolerance ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS ; RS synchrony ; CS ; rte ; CO ; RVPO ; RS synchrony ; CS ; biVP ; CO
tAPse ; PASp ; tAPse-to-PASp ratio ;TAPSe ;PASp ; cox regression ; Kaplan-meier ; tAPse ; PASp
cPET ; CHF ; exercise ; exercise ; rehabilitation
Human heart failure ;HF ; mRNA splicing ; v ; voltage-gated cardiac ; na+ channel α-subunit ; sCN5a ; truncated ; nonfunctional channels ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; anthracycline ; childhood malignant disease
économique Analysis ; Patient Management Interventions ; Heart Failure Cost-Effectiveness Model ; web-based simulation ; clinical ; laboratory characteristics ; evidence-based medications ; costs
natriuretic peptides ;NPs ; b-type NP ; n-terminal pro-B-type NP ; acute heart failure ; Emergency Department ; ed ; acute dyspnea
peak oxygen consumption ; VO2 ;ven ; vco2 slope ; exercise oscillatory ventilation ; eOV ; pressure ; end-tidal CO2 ;PETco2 ; cardiopulmonary exercise testing
Denmark ; bisphosphonates ; raloxifene
hypertension ; LV dilatation ; LV dysfunction ; MR ; MS ; mitral valve ; closure ; lesion ; systolic ; diastolic tethering ; MR ; MS
tolvaptan ; hyponatremia ; Japan ; congestive heart failure ; diuretic therapy ; serum sodium levels ; systolic function
longitudinal strain ; left ventricle ; echocardiographic ; cRT ; echocardiograms
platelet-activating factor ;PAf ; metabolic enzymes ; heart failure ; hz ; bmi-matched
acute care surgery ;ACs ; oHT ; transplantation ; medical therapy ;MT ; intravenous inotropes ; ventricular assist devices ;VADs
HFpf ; ivabradine ; ventricular filling pressure ; exercise ; implantation ; diastolic mitral flow velocity ; diastolic mitral annular velocity
renin-angiotensin-aldosterone system ;raas ; hfrEF ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; HFpEF
lVET ; unfavorable outcome
heart rate ; blood pressure ; renal function ; spironolactone ; RAS blockers ; β-blockers
cardiac performance ; β-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump ; reverse cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers therapy ; β-blockers therapy
congestive heart failure ; mitochondrial damage ; TAC ; mitochondrial proteome changes ; mitochondrial ; nonmitochondrial protein changes
myofibrillar ca(2+)-stimulated ATPase activity ; mRNA levels ; SR ca(2+)-pump ; phospholamban ; α-myosin heavy chain ; mRNA ; β-myosin heavy chain ; metoprolol
HDL ;HDL ;healthy ; CHF-NYHA-III ;HDl ;NYHA-IIIb ; ET ; CHF-NYHA-II ;HDl ;NYHA-II
inesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
md ; md ; md
baseline ; heart failure ; t1-mapping ; administration ; contrast agent
HF ; idiopathic dilated cardiomyopathy ; c'd ; ischemic ; SH ; valvular ; alcohol
ST2 ; functional capacity ; ambulatory patients ; HF ; Heart Failure ; controlled Trial Investigating Outcomes of Exercise Training ;HF-ACtion ; multicenter ; exercise training ; HF
cardiopulmonary exercise testing ; exercise rehabilitation ; patients ; chronic heart failure ;CHf ; CardioPulmonary Exercise Testing ; cPET ; exercise rehabilitation ; China
ischemic HF ; NYHA functional class IV ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
HF-ACtion ; HF ; ventricular ejection fractions ; HRQoL ; Kansas City Cardiomyopathy Questionnaire ; kccq
cRT ; systolic dysfunction ; resynchronization reVErses remodeling ; Systolic left v entricular dysfunction ; reVERSe ; left ventricular ;LV ; ejection fraction ;LVEF
glomerular filtration rate ; egFR ; diabetes ; cholesterol ; lDL-cholesterol ; CLCNKA GG genotype
echocardiography ; LV ; end-diastolic dimension ; LV end-diastolic pressure ;wall stress ; lung weight ; aCF ; sham group

spironolactone
Rate-control patients ; cardiac procedures ; cardioversions ; costs ; antiarrhythmic drugs
diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone Post myocardial infarction Heart failure Efficacy ; survival Study ; eheSUS ; post-myocardial infarction ; heart failure ; mortality ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; implantable cardioverter-defibrillator therapy ; MADit-crte ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
risk reduction ; h ; heart failure-related mortality ; sudden death
DASh ; sRD ; brachial systolic pressure ; hg ; central end-systolic pressure ; hg
hf ; obese ; body mass index ; black ethnicity ; idiopathic-dilated cardiomyopathy
all-cause mortality ; HF ; LVEF ; heart Failure Survey ; ISrael
ventricular ejection fraction ; World Health Organization ; idiopathic dilated cardiomyopathy ; negative coronary angiography
european Society of Cardiology guidelines ; hff ; heart failure ; LV ejection fraction ; non-dilated left ventricle ; diastolic dysfunction ; inimpaired LV relaxation ; LV diastolic stiffness ; LV filling pressures
β1ARs ; s1PR1s ; myocyte ; action on cAMP production ; receptors ; g-protein-coupled receptor kinase-2
PAf-cp ; PAf ; lyso-paf-AT ; PAf-AH ; lp-PLA2
heart failure ;mean ejection fraction ; cardiac rehabilitation ; Nordic walking
dRS-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal muscle mass ; t-score ; figure ; sarcopenic range muscle wasting ; t-score
testosterone group ; oxygen uptake ; Beck depression inventory ; leg strength ; Medical Outcomes ; Short-Form quality of life
RAS- ; β-blocker uptitrations ; all-cause mortality ; HF readmissions ; hFrEF ;hazard ratio ; hf
patients enrolled in Heart Failure ; controlled Trial Investigating Outcomes of Exercise Training ;HF-ACtion ; social support ; barriers to exercise ; social support score ;PSs ; barriers to exercise score ; btes
ST2 ; cardiovascular death ; HF hospitalization ; all-cause mortality
New York Heart Association ; cardiopulmonary exercise ; lean mass ; dual x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
dopamine ; nesiritide ; diuretic therapy ; renal function ; acute heart failure
crte ; New York Heart Association class III ; heart failure ; left ventricular ejection ; QRs ; echocardiographic evidence ; left ventricular dyssynchrony
left ventricular ;LV ; HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow ; mitral annulus velocities ; systole ; diastole
acute coronary syndromes ; CAD ; bNP ; NT-probNP ; CAD
HF ; lyso-paf-AT ; PAf-cp ; PAf ; PAf-AH ; lp-PLA2
sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve repairs ; transcatheter aortic valve ; surgery ; aortic valve replacement
cutoff value ; plasma N-terminal pro-B-type natriuretic peptide ;NT-probNP ; acute heart failure ;HF ; emergency department ; ed
cardiac troponin t ; ctnt ; N-terminal pro-B-type natriuretic peptide ;NT-probNP ; HF ; HF ; HF ; Atherosclerosis Risk in communautés ;ARIc
body mass index ;HR ; fat-free mass index
pd ; CHF ; cRF
reverse remodeling ; ejection fraction ; mortality ; HF ; dialysis
EH ; LV contractility ; LVEF ; LVEF ; ratio of systolic blood pressure ; end-systolic volume ; hg
echocardiography ; LV ; end-diastolic volume index ; mL/m2 ; LV ejection fraction ; mild MR ; ms ; ms ; mva ; pressure gradient ; hg
double-blind ; placebo-controlled clinical trial ; renal Optimization Strategies Evaluation ;ROSe ; acute heart failure ; renal dysfunction ; glomerular filtration
BETs ; chromatin-mediated signal transduction ; Pol II ; co-activating transcription factor networks ; HF pathogenesis ; nuclear factor of activated T cells ; nFAT ; nuclear factor-κb ;NF-κb ; transcription factor
mortality ; hospitalization ; cardiovascular events ; myocardial infarction ; congestive heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
all-cause ; cardiovascular mortality
EO-cFUs ; diabetes ; EO-cFU ; diabetes ; EO-cFU ; VO2 ; diabetes ; EO-cFUs
immunoblotting ; radioenzymatic- ; fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; ca2 ; myocardial tissues ; cardiomyocytes ; HF
eAST ; atrial fibrillation ; Stroke prevention Trial ; AF ; stroke ; guideline-mandated usual care ; rhythm control therapy
Exercise capacity ; peak oxygen consumption ;VO2 ; ml/kg/min ; QOL ; Minnesota Living with Heart Failure ; mlHF ; heart failure-related QOL
TAC-induced proteomic alterations ; mitochondrial-targeted peptide SS31 ; perturbed mitochondrial function ; pathway alterations ; TAC ; mitochondrial-targeted peptide drugs ; heart failure
ventricular ejection fraction ; patients ; HF ; ventricular ejection fraction ; hospital ; physicians ; acute ; outpatient settings ; financier costs
hf ; left ventricular ;LV ; ejection fraction ; hf ; echo-Doppler studies ; pro-brain-type natriuretic peptide
low-volume EDs ; hospitalized ; medium ; high-volume EDs
cardiac transplant ; ECCT ; diabetes mellitus ; chronic kidney disease ; glomerular filtration
hABC Battery scores ; Health ABC ; HF Risk Model ; discrimination ; c-index ;net-reclassification-improvement ; HF
cf ; RMsea ; Self-Care Maintenance Scale ; cf ; RMsea ; Self-Care management Scale ; cf ; RMsea ; Self-Care Confidence scale
BAT ; distance walked ; quality-of-life score ; NYha functional class ranking
hypoalbuminemia ; postoperative normalization ; albumin levels ; hypoalbuminemia ; decreasing albumin ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; complications ; kidney infection ; urinary tract infection ;UTI
patients ; heart failure ;HF ; ischemic ; nonischemic cardiomyopathies ; pharmacological armamentarium ; implantable cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; ventricular assist devices
SAF ; pf ; figure ; central venous pressure ; hg ; hg ; svr ; hg ; hg ; cardiac index
admission median bNP ; EF ; EF ; bNP ; bNP
heart failure admission ; heart transplantation ;LV assist device ; death ; ischemic cause
LV ejection fraction ; vitesse ; circumferential shortening ; elastance ; contractile efficiency ; aCF ; aCF ; allopurinol rats ; o2 consumption rate ; cardiomyocytes ; extracellular flux analyzer
HFpEF ; LV structure ; normal geometry ; LV hypertrophy ;LVh ; relative wall thickness ;RWt ; CR ; LVh ; rWT ; hz
angiotensin receptor neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; preserved ejection fraction
blood pressure ; hg ; mitral valve plasty ; degenerative MR ; p3 prolapse ; chordal ruptures ; triangular resection ; edge-to-edge anastomosis ; ring annuloplasty ; Physio Ring ; edwards Lifesciences ; irvine ; ca
shuttle walk test ; oxygen uptake ; muscular strength ; echocardiographic measures ; pro-brain natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ; health-related quality of life ;Minnesota Living with Heart Failure Questionnaire ; Medical
LVEF ; long-term mortality ; LVEF ; age-by-LVEF
rats ;Wistar-Kyoto ; lean ZSF1 ; obese ZSF1 ; obese ZSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic evaluations ; hemodynamically
Kaplan-meier curves ; log-rank testing ; risk stratification
af type ; long-standing persistent AF ; hypertension ; maintenance ; sinus rhythm ;hazard ratio
HF-ref ; NYHA functional class II ; egFR ; potassium ; eplerenone ; hyperkalemia ; wRF
ff ; FM ; body fat distribution ; dual energy X-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ;CHf ;cc ; CHF ; myocardial infarction-both
drug dose ; spironolactone ; end point of death ; hospitalization ; HF ; AAs ;hazard ratio
pulmonary arterial hypertension ; inoperable chronic thromboembolic pulmonary hypertension ; impaired right ventricular pump ; pulmonary arterial hypertension medication ; stress echocardiography ; cardiopulmonary exercise
cardiovascular death ; HF hospitalization ; btes ; btes ; btes ; cardiovascular death ; HF
index ED visit ; low-volume ED ; 30-day death ; all-cause readmission ; eds
implantable cardioverter-defibrillator deactivation ; implantation ; implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ; left atrial area ; pulmonary vascular resistance ; cardiac
HF units ; systolic ; left ventricular ejection fraction ; HF ; New York Heart Association ; echocardiographic ; cardiopulmonary exercise
heart failure ; ABCd classification ; American College of Cardiology ; acc ; acc ;American Heart association ;AHA ; New York Heart association ;NYHA ; structural heart disease ; heart failure
mva ; continuity equation ;LV ; end-diastolic volume ; LV ; end-systolic volume ; mitral filling flow ; mva ; velocity time ; mitral filling flow ; continuous wave doppler echocardiography ; MR ; mitral valve plasty
statitistical significance ; RM ; all-cause mortality ; sts HH ; ms ; office hours
HFPSI ; Ann Arbor Veterans' Affairs ; HF clinic ;VA-RT ; VA ; HFPSI ; HFPSI ; HFPSI
AAs ; spironolactone dose ; hyperkalemia ; potassium ; hypokalemia
LVEF ; long-term mortality ; LVEF ;hazard ratio ; LVEF
HFpEF ; HFpEF ; gender ; NYha class III ; distance covered ; mwt ; mlt ; adherence ; medications
pulmonary arterial systolic pressure ;PASp ; right ventricular ;RV ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
CAD ; electrocardiographic Q waves ; left bundle branch block ; nondiabetes ; dyslipidemia ; hypertension ; tobacco use
receiver operating characteristic curve ; auc ; ratios ; PCWP ;septal ; e-elateral ; e-emean
trastuzumab-treated patients ; coronary artery disease ; h ; hypertension ; h
LVEF ; clinical composite response ; cRT ON ; cRT OFF ; LV end systolic volume index ; mL/m ; LV mass
TGF-β signaling ; TGF-β receptor ; smad ; small-molecule inhibitors ; c-Kit+ cell yield ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog ; c-Kit+ cell differentiation ; cardiomyocyte-like cells
hfrf ; diuretics ; co-morbidities ; mwt ; NYha class III
surgery ; HF ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; mitral valve ; mva ; pression gradient ; hg
systolic heart failure ; ivabradine ; SHIFT ;Systolic Heart Failure Treatment ; If inhibitor ivabradine Trial ; ivabradine ; echocardiographic substudy
Hazard ratios ; multivariate regression ; tAPse/PASp ; hg ;hazard ratio ; tAPse ; New York Heart Association functional class
Renal function ; Chronic Kidney Disease Epidemiology ; glomerular filtration rate ; egFR
paraDIGm-HF ; chronic heart failure ; systolic dysfunction ;LVEF ; functional class NYHA II-III ; bNP ; bNP ;cardiovascular death ; hospitalization for heart failure ; ARNI ; sacubiltril ; valsartan
LV reverse remodeling ; pre-CRT ; ventricle ; left atrial ; ventricular end-diastolic dimension ; ventricular fractional area change
hyperkalemia ; African Americans ; AAs ; non-AAs ; New York Heart Association ;NYHA ; HF ; left ventricular dysfunction ; spironolactone ; aldactone Evaluation Study ;RALes
iRS1 ; iRS2 ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; iRS1 ; iRS2 ; heart-specific ; iRS1 ; iRS2 gene double-knockout ; h-dKO ; liver-specific iRS1 ; iRS2 double-knockout ; l-dKO
b-type natriuretic peptide ; n-terminal pro-B-type natriuretic peptide ; coronary artery disease ; bNP ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers
ivabradine ; therapy ; ivabradine
liberal transfusion protocols ; mortality ; aggressive protocols ; acute coronary syndrome
death ; unplanned readmission
hEK ; embryonic kidney ; sphingosine-1-phosphate ; s1PR1 agonist ; isoproterenol ; β-adrenergic receptor agonist
Kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; depressive symptoms ; beck depression inventory ; depression ; natriuretic peptide ; endothelial function ;flow-mediated dilatation ; ventricular diastolic function
cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration
in conjunction ; diastolic function ; ventricular-arterial coupling
disease risk score ; dRS ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
revascularization ; coronary artery bypass surgery ; hazard ratio ; percutaneous coronary intervention ; systolic blood pressure ; left bundle branch block pattern ; baseline electrocardiogram
biomedical treatment ; biomedical treatment ; CHm ; ventricular ejection fraction ; left ventricular diastolic end diameter
heart failure patients ; left ventricular ejection fraction ; Arg16 ; grn27 ; gly16 ; figure ; β2-receptor ; carvedilol ; metoprolol
low-volume ED ; death ;hospitalization ; ed
Health Buddy Program ; risk-adjusted all-cause mortality ;hazard ratio ;HR ; confidence interval ; CI ; quarterly inpatient admissions
multivariable-adjusted hazard ratios ; Mediterranean diet score ; DASh
ctnt ; NT-probNP ; aRIC HF ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; HF ; receiver operating characteristic curve ; auc ; discrimination ; net reclassification improvement ; nRI ; model fit
eplerenone ; hyperkalemia ; renal function ; wRF ; EMPHASIS-HF ; heart failure ; reduced ejection fraction ;HF-ref ; New York Heart Association ;NYHA ; glomerular filtration rate ; egFR ; serum potassium
low-dose nesiritide ; 72-hour cumulative urine volume ;nesiritide ; figure ; cystatin C ;nesiritide
Nordic walking ; functional capacity ; mwt ; physical activity ; depressive symptoms ;Hospital anxiety ; depression
hyperkalemia ; wRF ; diabetes ; egFR ; systolic blood pressure ; hg ; potassium ; hyperkalemia ;drug discontinuation ; hospitalization ; wRF ;hospitalization ; HF ; cardiovascular mortality
PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ;lyso-paf-AT ; dithiothreitol ; dt-insensitive CDp choline ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; pf-cp ; catabolic isoenzymes ;paf-acetylhydrolase ; pf-abb ; lipoprotein-associated phospholipase a2 ; lp-PLA2
ivabradine group ; baseline ; follow-up exercise capacity ; METs ; peak oxygen uptake ; exercise-induced ; peak early diastolic mitral flow velocity ; early diastolic mitral annular velocity
CHF ; implants ; ht chest radiation ; hypertension ; genes coding ; NAD ; ph-oxidase subunit RAC2 ; hf ; hf ; doxorubicin efflux transporter ABCc2
NYha classification ; class III ; class II ; implantation Status ; Duke Activity Status Index ; Kansas City Cardiomyopathy Questionnaire ; walk test distance
low-dose dopamine ; 72-hour cumulative urine volume ;dopamine ; mll ; cystatin c level ;dopamine
implantation ; baseline glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; ventricular ejection fraction ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; New York Heart Association class ; atrial fibrillation ; congestive HF
peak oxygen uptake ; hazard ratio ; confidence interval ; ventilatory efficiency slope ; hemoglobin ; ventricular ejection fraction ; renal function ; renal disease ; sodium
Kansas City Cardiomyopathy Questionnaire ; Minnesota Living with Heart Failure Questionnaire ; Beck depression inventory ; zung ; flow-mediated dilatation diameter ; Fes ; natriuretic peptide ; mitral e/e ; wave ratio
